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ABSTRACT 
Background and purpose 
Early pregnancy problems, including miscarriage, ectopic pregnancy and 
pregnancy of unknown location, occur commonly and have significant medical, 
psychological and economic consequences.  Biochemical markers are 
increasingly being used as an adjunct to ultrasonography and this thesis 
describes three studies exploring the use of novel biochemical markers in the 
diagnosis and management of early pregnancy problems. 
Materials and methods 
These are observational studies of women in early pregnancy recruited at 
Sunderland Royal Hospital and King’s College Hospital.  Serum samples were 
taken from women in early pregnancy and lectin affinity chromatography used 
to characterise the glycosylation of hCG by gestational age and by pregnancy 
outcome.  Women with a diagnosis of a miscarriage, ectopic pregnancy or 
pregnancy of unknown location had serum levels of hCG, progesterone, inhibin 
A, IGFBP-1 and inhibin proαC quantified, and statistical analysis was used to 
see if spontaneous resolution of the pregnancies could be predicted.   
Results 
Lectin-affinity chromatography reveals five major glyco-isoforms of hCG in early 
pregnancy, the expression of which changes with gestational age and by 
pregnancy outcome.  The novel markers of the luteo-trophoblastic axis inhibin 
A, IGFBP-1 and inhibin proαC are found not to be clinically useful in the 
prediction of spontaneously resolving PULs although when used in the decision 
trees developed by Elson in 2005, they are useful for predicting spontaneous 
resolution of miscarriages and failed pregnancies. 
Conclusions 
Novel biochemical markers have the potential to be a useful addition in the 
management of early pregnancy problems.  Further studies are required to 
explore the physiological basis of these findings and the clinical applicability of 
these tools. 
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CHAPTER 1.  INTRODUCTION 
Early pregnancy loss is perhaps the most common medical problem in women 
of reproductive age.  These conditions are a large burden to health services as 
well as to the physical and psychological wellbeing of women and their partners.  
In recent times there have been major changes in our approach to the 
management of early pregnancy problems.  With the introduction of early 
pregnancy assessment units and transvaginal ultrasonography we have moved 
away from an in-patient and surgical approach, to outpatient services and a 
more conservative approach to management.  
Transvaginal ultrasound is now used routinely in the assessment of early 
pregnancy problems.  This allows a more detailed assessment at earlier 
gestations than was previous possible.  These findings are often used in 
combination with biochemical markers to give a more complete evaluation or 
‘profile’ of the pregnancy.  Serum levels of human chorionic gonadotrophin 
(hCG) and progesterone are the most commonly used biochemical markers, the 
optimum way to utilize them in the diagnosis and management of early 
pregnancy problems remains contentious.  
The move away from surgical treatment for early pregnancy problems has 
economic and clinical advantages.  Problems occur however when medical or 
expectant management is unsuccessful and surgical intervention is required at 
a later date, often in an ‘emergency’ situation.  The lack of well-defined criteria 
to differentiate between pregnancies that will spontaneously resolve and those 
that will not is an ongoing problem for expectant management and is certainly 
off-putting for patients and clinicians.  Expectant management often takes 
weeks to complete and success rates vary widely.  Failure of expectant 
management after prolonged follow-up is particularly disappointing for women 
and reduces overall benefits of the management strategy.  
A number of novel biochemical markers of the luteal-trophoblastic axis have 
emerged in the last decade.  The aim of this thesis was to investigate these 
novel biochemical markers in the diagnosis and management of early 
pregnancy complications.  In particular I have tried to identify parameters, which 
can reliably predict the success of expectant management in women with failing 
pregnancies.  The ability to do so would not only reduce the need for follow-up 
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but also decrease the need for surgery for both diagnostic and therapeutic 
indications.  The ability to estimate the likelihood of final outcome would allow 
us to counsel patients appropriately and is likely to increase the uptake of 
expectant management by both clinicians and patients.  This would improve the 
overall care of women with early pregnancy problems.   
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CHAPTER 2.  LITERATURE REVIEW 
2.1 NORMAL EARLY PREGNANCY 
2.1.1  Fertilisation, implantation and early development 
Following ovulation the ovum is taken up by the fimbrial end of the Fallopian 
tube and is wafted medially by the rhythmical action of the cilia.  Fertilisation of 
the ovum by spermatozoa occurs either in the peritoneal cavity or within the 
Fallopian tube.  During the following 48 hours the conceptus travels along the 
Fallopian tube and into the uterine cavity.  Within 30 hours of fertilisation the 
first cell division occurs, in which the fertilised ovum splits into two separate 
cells.  On the fifth day after conception, an additional round of division causes 
the 32-celled morula to reach the blastocyst stage.  This hollow ball is 
composed of an inner cell mass, eventually giving rise to the fetal and 
embryonic tissues, and an attached outer shell of cells known as the 
trophoblast, which will ultimately give rise to the chorion.  By the tenth day, the 
invading trophoblast forms two distinct layers – the cytotrophoblast and the 
syncytiotrophoblast.  The cytotrophoblast (the inner layer) is composed of 
individual, well defined and rapidly proliferating cells.  The outer and thicker 
layer, the syncytiotrophoblast, comprises of multinucleated cells with indistinct 
cell borders (Anin et al., 2004).   
The conceptus attaches to the secretory endometrium of the uterus by 5 days 
post ovulation but it is not until day 12 that the blastocyst has burrowed into the 
endometrium to such an extent that it is completely embedded.  There is initial 
decidualisation at the implantation site, which eventually extends to the whole 
endometrium.  The trophoblast cells produce a proteolytic enzyme which allows 
invasion into the endometrium.  The trophoblastic cells will form the extra-
embryonic tissue.  The trophoblast differentiates in two ways – the villous and 
the extravillous trophoblast.  The villous trophoblast remains attached to the 
villous membrane, this is responsible for maternal-fetal gas and nutrient 
exchange, and hormone secretion.  The cells of the extravillous trophoblast 
proliferate from the tips of anchoring chorionic villi and migrate through the 
maternal tissues towards decidual arterial walls (interstitial invasion) (Lyall, 
2002), or infiltrate the lumens and walls of arteries to cause endovascular 
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invasion (Kaufmann et al., 2003).  Endometrial arteries do not communicate 
with the intervillous space before 12 weeks gestation because aggregates of 
trophoblast cells derived from the cytotrophoblast shell plug their distal 
segments.  This protects the conceptus from high oxygen levels during this 
critical stage of development (Burton et al., 1999).  The definitive structure of 
the placenta is apparent as early as day 21 post ovulation however the 
uteroplacental circulation is not fully functional until the end of the first trimester 
(Hustin & Jauniaux, 2000).  Placentation, along with other early gestational 
processes such as implantation, is one of the most important determinants of 
pregnancy outcome.  
 
2.1.2  Biochemistry in early pregnancy 
The syncytiotrophoblast of the developing placenta plays a key part in hormone, 
protein and growth factor production in early pregnancy.  Human chorionic 
gonadotropin (hCG) is secreted by the syncytiotrophoblast almost immediately 
after implantation.  This maintains the function of the corpus luteum which in 
turn secretes hormones and growth factors which are essential for the 
maintenance of early pregnancy.  This activity of the corpus luteum decreases 
after the seventh week of pregnancy at which time the trophoblast and decidua 
take over as the main hormone-producing unit.  
 
Human chorionic gonadotrophin 
The glycoprotein hormone human chorionic gonadotrophin (hCG) has a 
molecular weight of 36,700d (Midgley & Pierce, 1962) and was first identified in 
1927 (Ascheim & Zondek, 1927).  It consists of two dissimilar subunits, α and β, 
which are glycosylated and non-covalently bound.  The hCG-α subunit is 
virtually identical to that of the human pituitary glycoprotein hormones, 
luteinising hormone (LH), follicle stimulating hormone (FSH) and thyroid 
stimulating hormone (TSH) (Bahl 1969a; Canfield et al., 1971).  The 
characteristic biological and immunological identities of these hormones are 
conferred by their specific β-subunits (Pierce and Parsons, 1981).  Synthesis of 
hCG occurs predominantly within trophoblast cells of the blastocyst, the α and β 
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subunits being coded for separately on chromosomes 6 and 19 respectively 
(Fiddes & Goodman, 1981; Boorstem et al, 1982).  Post-translational 
glycosylation comprises the addition of two N-linked oligosaccharides to each 
subunit; on amino acids 52 and 78 (α subunit) and 13 and 30 (β subunit).  In 
addition to N-linked oligosaccharides, 4 O-linked oligosaccharides are located 
within the hCG-β–COOH terminus (Bahl, 1969b).  HCG is metabolised by the 
kidney, it is desialated and then excreted into urine (Birken et al., 1996).  
HCG secretion begins no later than day 7 in the blastocyst stage (Lopata & 
Hay, 1989).  It has been shown that its level in maternal serum doubles over 
1.4-1.6 days from the time of first detection to the thirty-fifth day of pregnancy, 
and then doubles over 2.0-2.7 days from the thirty-fifth to the forty-second day 
(Pittaway et al., 1985).  The pattern of hCG concentration throughout pregnancy 
is shown in Figure 1.  The half-life of hCG is 32 to 37 hours and the levels of 
hCG are approximately 1000 IU/L at around 4 weeks of pregnancy, the time of 
initial visualisation of a gestational sac on transvaginal ultrasound scan.  HCG 
secretion increases with advancing gestational age, reaching a maximal level of 
50,000 to 100,000 IU/L at 10 weeks gestation.  HCG levels decrease to around 
10,000 to 20,000 IU/L by 20 weeks and this plateau is maintained for the rest of 
pregnancy.  Most commercially available monoclonal antibody-based urine 
pregnancy tests can detect the presence of hCG at a level above 25 IU/L, which 
corresponds to days 24 to 25 of a regular 28-day cycle.  Many different 
laboratory assay kits exist which are calibrated against different reference 
preparations of hCG.  βhCG may exist in the blood as part of the intact hCG 
molecule (α and β subunits) or as free βhCG.  Assay kits measure either intact 
hCG, βhCG or total hCG (intact plus βhCG).  These need to be taken into 
account when comparing results from different investigators and appropriate 
values need to be developed for individual medical centres.   
In primate studies it is the exponential increase in hCG levels produced by the 
implanting embryo and syncytiotrophoblast that appears to prolong the 
functional lifespan of the corpus luteum (Zeleznik, 1998).  In response to hCG, 
the corpus luteum produces increasing concentrations of progesterone, 17 α-
hydroxyprogesterone (17-OHP) and oestradiol, and stimulates the secretion of 
relaxin.  hCG maintains the steroidogenesis of the corpus luteum until the ninth 
to tenth week of pregnancy by which time placental steroidogenesis is 
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established and the role is entirely taken over by the placenta.  It is also thought 
that hCG produced by the placenta has a number of autocrine and paracrine 
actions.  These include involvement with the autoregulation of placental 
steriodogenesis (Menon & Jaffe, 1973), and increasing syncytium formation 
(Yang et al., 2003).  There is also evidence that hCG modulates trophoblast 
invasion by interfering with endometrial matrix metalloproteinases (MMPs) and 
their tissue inhibitors (Licht et al., 2001) and influences endometrial 
differentiation by modulating prolactin and insulin-like growth factor binding 
protein-1 (IGFBP-1) at the implantation site (Fluhr et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Schematic representation of concentration of human chorionic 
gonadotrophin (hCG) throughout gestation.  
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Using antibodies to a linear epitope on the β-hCG-COOH terminus, a 
hyperglycosylated (H-hCG) form of standard or regular hCG has been identified 
as the predominant structure in early pregnancy (Sasaki et al., 2008).  H-hCG 
differs from hCG in both the branching and sialic acid content of N- and O-
linked oligosaccharides (Elliott et al., 1997; Cole et al., 2003).  H-hCG is a 
product of stem cytotrophoblast cells whereas hCG is produced by 
syncytiotrophoblasts (Kovalevskaya et al., 2002a; Cole et al., 2006).  The 
expression of H-hCG as a proportion of total hCG declines rapidly in early 
pregnancy from 92% of total hCG at 3 weeks gestation to <2% total hCG by the 
second trimester (Cole et al., 2003).  The relative proportion of H-hCG to total 
hCG has been shown to be clinically significant.  In particular implantation has 
been shown to depend upon H-hCG.  Low H-hCG levels are predictive of early 
pregnancy loss (Sutton-Riley et al., 2006) and high concentrations are seen in 
choriocarcinoma (Khanlian et al., 2003).  
 
Inhibins 
Inhibins are heterodimeric glycoprotein hormones consisting of disulfide-linked 
alpha and beta subunits.  Inhibin A has a molecular weight of 32kd and is 
composed of inhibin α and βA subunits.  It is produced by the corpus luteum 
during the luteal phase of the ovarian cycle (Muttukrishna et al., 1994) and in 
early pregnancy (Illingworth et al., 1996) and is also produced by the 
syncytiotrophoblast in early pregnancy (Birdsall et al., 1997).  There is 
conflicting evidence about which is the major source of inhibin production in 
early pregnancy.  Santoro et al., (1992) looked at inhibin levels in women with 
premature ovarian failure and donor in vitro fertilisation (IVF) pregnancies i.e. 
aluteal women.  They showed that there was no early rise in inhibin as seen in 
normal pregnancies, although the levels did reach normal levels towards the 
end of the first trimester.  Lockwood et al., (1997) examined this further by 
comparing blood samples of women who became pregnant following IVF with 
fresh embryo transfer i.e. luteal women, with those who became pregnant 
following IVF with frozen embryo transfer i.e. aluteal women.  They concluded 
that there was no difference in luteal and aluteal pregnancies and that therefore 
the fetoplacental unit must be the major source of inhibin A in early pregnancy.   
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Treetampinich et al., (2000) however found that in IVF cycles inhibin A levels 
were significantly lower in the absence of functioning ovaries and in natural 
cycles compared with concentrations after ovarian stimulation.  They also found 
that inhibin A concentrations were not significantly different between singleton 
and multiple pregnancies and therefore concluded that the corpus luteum is the 
major source of circulating inhibin A in early pregnancy. 
In 2002 Muttukrishna et al., found decreased maternal serum levels of inhibin A 
in pregnancies that went on to miscarry and in 2006 Hwang et al., showed a 
significant association between the number of fetuses and maternal inhibin A 
levels in a study of singleton and multiple pregnancies following IVF and 
embryo transfer.  These also confirm that the trophoblast is the major source of 
inhibin A after the luteo-placental shift in early pregnancy.  
Circulating inhibin A levels are at detectable levels by 4 weeks gestation 
(Lockwood et al., 1997) and climb to a peak at 8-10 weeks of gestation 
(Tovanabutra et al., 1993; Illingworth et al., 1996, Phupong, Hanprasertpong & 
Honsawek, 2008).  Levels then fall slightly at 16 weeks and thereafter increase 
progressively to maximal concentrations in week 36 (Fowler et al., 1998).  The 
clearance of inhibin A is fast with a short half-life of around 45 minutes 
(Muttukrishna et al., 1997).  Inhibin A is thought to be involved in regulating 
placental hCG production by inducing changes in gonadotrophin-releasing 
hormone (GnRH) secretion (Petraglia et al., 1987).  It is also thought to play a 
part in the cell signalling and therefore possibly trophoblast invasion (Debieve et 
al., 2000).  Animal studies have also suggested a role of inhibin A in maintaining 
luteal progesterone output (Webley et al., 1994).  Its function in humans 
however, remains unclear.  It has a shorter half-life than either hCG or 
progesterone and therefore may be more sensitive at reflecting changes in the 
trophoblast.  Lower levels have already been demonstrated in women with 
biochemical pregnancies and missed miscarriages (Glennon Phipps et al., 
2000; Muttukrishna et al., 2002).  In women with induced pregnancy 
termination, inhibin A levels have been shown to fall after the administration of 
misoprostol, which interrupts trophoblastic blood flow and leads to expulsion of 
the pregnancy (Lahiri et al., 2003).  Illingworth et al., (1996) examined inhibin A 
levels in ectopic pregnancies, complete and incomplete miscarriages, and 
ongoing pregnancies, and found no significant differences between the groups.  
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Phipps et al., (2000) found that among dual biomarker combinations for 
differentiating viable from nonviable pregnancies, the addition of inhibin A to 
progesterone improved the specificity but not sensitivity of the test.  A more 
recent pilot study (Johns et al., 2007) however, using logistic regression 
analysis, found that inhibin A alone is the best predictor of first trimester 
miscarriage.  Kirk et al. (2009) found that serum inhibin A levels may be of 
some use in predicting failing PULs and IUPs in the PUL population.  
Inhibin pro-αC, a pre-cursor protein of the inhibin α subunit, circulates as a 
functionally inactive monomer and as part of high molecular weight functional 
dimers.  Inhibin pro-αC-related immunoreactivity (inhibin pro-αC-RI) is a 
cumulative measurement of monomeric pro-αC subunit and pro-α containing 
inhibins (Illingworth et al., 1996).  Inhibin pro-αC-RI has been found to peak at 
around day 16 after conception and then fall to a nadir at 16 weeks of gestation, 
before increasing to a second peak at 36 weeks (Illingworth et al., 1996; Fowler 
et al., 1998).  Despite the secondary rise from the early second trimester, 
absolute levels are at their highest in very early pregnancy (Fowler et al., 1998).  
In their study of 334 women undergoing IVF, Tong et al. (2004) found that this 
early peak in circulating inhibin pro-αC in very early pregnancy was a consistent 
and specific feature of clinical pregnancy.  Illingworth et al. (1996) also found 
that inhibin pro-αC-RI concentration was an indicator of continuing pregnancy 
viability, better than either hCG or inhibin A.  
In their study of aluteal and luteal pregnancies Lockwood et al. (1997) 
compared serial levels of pro-αC-RI in early pregnancy in these two groups.  
They found that pro-αC-RI was significantly higher in those pregnancies with 
multiple corpora lutea compared to those with single corpora lutea and 
significantly lower in those women with conceptions from frozen embryos i.e. 
aluteal than those with fresh embryos i.e. luteal.  They therefore concluded that 
the corpus luteum must be the major source in early pregnancy.  Fowler et al., 
(1998) identified a small rise in inhibin A levels and a peak of hCG coinciding 
with the fall in maternal venous pro-αC concentrations after week 9.  These are 
likely to reflect the luteal to placental shift in support for the pregnancy.  Inhibin 
pro-αC is secreted by the placenta into the fetal circulation at term, and is 
thought to play a role as a paracrine and endocrine regulator of placental 
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function (Riley et al., 2000). IVF protocols involving complete ovarian 
suppression (and therefore absence of luteal tissue) are compatible with 
successful pregnancy (Lockwood et al., 1998), demonstrating that Inhibin pro-
αC is not, however, essential for successful pregnancy. 
The early increase in inhibin pro-αC-RI in human pregnancy (Illingworth et al., 
1996, Lockwood et al., 1997) supports findings from animal models.  Webley et 
al., (1994) found that in the marmoset monkey circulating inhibin pro-αC-RI 
were significantly elevated above ‘normal’ luteal phase concentrations as early 
as 5 days after ovulation.  Measurements of pro-αC-RI concentrations could 
thus serve as a useful marker of luteal sufficiency during the establishment of a 
pregnancy.  
 
Steroids 
Progesterone 
Progesterone is a C-21 steroid hormone derived from cholesterol.  It is one of 
the primary products of the corpus luteum and plays a pivotal role in the 
establishment and maintenance of pregnancy (Spencer & Bazer, 2004).  
Progesterone acts on the uterus to stimulate and maintain uterine functions that 
are permissive to early embryonic development, implantation, placentation and 
successful fetal and placental development to term.  These include endometrial 
secretory changes, endometrial decidualization, myometrial quiescence, 
production of a number of endometrial proteins (such has PAPP and PP14), 
and suppression of matrix metalloproteinases (Schindler, 2004).  Recent 
evidence suggests that the action of progesterone in the endometrium is 
complex, acting directly (endocrine) and indirectly (paracrine) through both the 
induction and inhibition of gene expression (Lessey, 2003).  
Although progesterone originates almost entirely from the corpus luteum before 
7 weeks of gestation, its production shifts more to the placenta after the seventh 
week, and placental progesterone is sufficient to maintain the pregnancy from 
this point onwards.  From 9 weeks gestation the trophoblast is the dominant 
source of progesterone (Csapo et al., 1973).  Progesterone concentrations in 
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the maternal blood are less than 2 nmol/L during the follicular phase of the 
normal menstrual cycle (Abraham et al., 1972; Lindberg et al., 1974) rising to 2-
4nmol/L on the day of the LH surge and rising to a plateau of 20-70 nmol/L over 
the subsequent 7 days.  Concentrations rise until 7 weeks of gestation and then 
remain at a plateau until 10 weeks of gestation, from when concentrations 
gradually increase to term (see Figure 2).  At term, progesterone concentrations 
can range from 200 to 600 nmol/L (Tulchinsky et al., 1972).  Most of the 
progesterone in the maternal circulation is metabolised to pregnanediol and is 
excreted in the urine as glucuronide.  
The ability of antiprogesterone agents to induce abortion confirms 
progesterone’s crucial role in the maintenance of pregnancy (Baulieu, 1989).  It 
is thought that it may act by inhibiting T-lymphocytic cell-mediated responses 
involved in tissue rejection.  Studies of human trophoblast implanted into 
rodents showed that progesterone promoted survival, and thus suggested that it 
is progesterone that blocks the cellular response to foreign antigens (Siiteri et 
al., 1977).  Progesterone is known to be a potent inhibitor of leukaemia 
inhibitory factor (LIF) which itself plays an important role in trophoblastic 
invasion (Sunder & Lenton, 2000).  Synthetic progestagens have been shown 
to upregulate nitric oxide synthase in the endometrium and nitric oxide appears 
to play a role in the maintenance of uterine quiescence (Cameron & Campbell, 
1998).  
Progesterone production in early pregnancy reflects the dynamics of the corpus 
luteal-trophoblast axis and the status of the trophoblastic tissue.  As 
progesterone has a shorter half-life than hCG, the progesterone level will reflect 
any change in the dynamics of the pregnancy earlier.  In their prospective 
cohort study Plante et al., (2008) found that of the single biomarkers, 
progesterone had the greatest diagnostic accuracy in predicting pregnancy 
viability.  
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Figure 2. Schematic representations of concentrations of progesterone 
during the course of human pregnancy.                                                    
 
17 α-hydroxyprogesterone 
17 α-hydroxyprogesterone (17-OHP) is a steroid secreted in parallel to 
progesterone from the corpus luteum (Tulchinsky et al., 1972).  The plasma 
concentration of 17-OHP rises steeply following conception to levels of 2.6 
ng/mL in the third week of pregnancy to 5.8ng/mL at the fifth week and then 
declines to reach a nadir in the 13th week.  17-OHP values reflect corpus luteum 
function, since the placenta does not have 17 α-hydroxylase to participate in the 
production of this metabolite (Schindler, 2004).  The importance of the corpus 
luteum in early pregnancy has been known for a long time, supported by the 
clinical finding that removal of the corpus luteum in early pregnancy (before the 
8th week of gestation) is followed by miscarriage (Marthy et al., 1970).  Little is 
known of the functional role of 17-OHP but levels have been shown to be lower 
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in nonviable intrauterine pregnancies and ectopic pregnancies in a small 
number of studies (Check et al., 1990; Choe et al, 1992; Hubinont, Thomas & 
Schwers, 1987).  
 
Placental Growth Factors 
Insulin-like growth factor binding protein 1 (IGFBP-1) is one of six proteins that 
specifically binds insulin like growth factors (IGFs) in body fluids and tissues 
(Shimasaki & Ling, 1992).  Insulin-like growth factors (IGF-I and IGF-II), their 
receptors (IGF-Rs) and IGF-binding proteins (IGFBPs) have vital roles in the 
regulation of proliferation, differentiation, migration, survival and specific 
functions of many cell types (Jones & Clemmons, 1995).  IGFBPs prolong the 
half-life of IGFs and modulate IGF activities and bioavailabilities.  IGFBP-1 
contains 234 amino acids and has a molecular mass of 25kd.  The human 
IGFBP-1 gene is located on chromosome 7 and IGFBP-1 (also known as 
placental protein 12) is synthesised in large amounts by the decidua of early 
pregnancy (Rutanen, 1992).  It is the predominant IGFBP in amniotic fluid and a 
major insulin-like growth factor (IGF) binding species in fetal plasma (Drop et 
al., 1984).  It is one of the most important decidual secretory products, with 
important roles at the embryo-maternal interface in the regulation of placental 
development, embryo implantation and fetal growth.   
The concentration of IGFBP-1 in the maternal circulation increases during 
pregnancy.  There is a rapid rise in the first trimester reaching a peak at 12-16 
weeks and levels then decrease after 33 weeks. (Bell, 1988; Crossey et al., 
2002).  Concentrations are particularly high in decidualized stromal cells and 
IGFBP-1 is one of the best markers of decidualization (Dunn et al., 2003).  In 
the fetus IGFBP-1 is produced in the liver and pancreas.  The exact function of 
this protein is unclear but it may be present to modulate the potent growth 
induction by IGF-I, an agent known to be up-regulated by oestrogen (Murphy et 
al., 1987).  It has also been suggested that IGFBP-1 modulates trophoblast 
invasiveness, acting as a barrier to trophoblast migration (Irwin & Giudice, 
1998).  Any disruption to this interface may therefore theoretically be reflected in 
the levels of IGFBP-1.  IGFBP-1 is a local modulator of IGF action in fetal 
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growth (Ben Lagha et al., 2006) and it is also able to mediate progesterone-
induced decidualization (Matsumoto et al., 2008).  
Two hypotheses exist for the action of IGFBP-1 in early placentation.  One is 
that higher levels of IGFBP-1 inhibit binding of trophoblast to the decidual cells 
(Irwin & Giudice, 1998).  The second is that there is over-production of IGFBP-1 
by the deciduum in response to defective implantation.  In their study 
investigating the biochemical markers in the prediction of successful expectant 
management of miscarriage, Elson et al., (2005a) found that the presence of a 
raised level of IGFBP-1 was associated with an increased chance of successful 
expectant management.  This suggests that the high level reflect a defect in 
attachment of the trophoblast to the decidua thus resulting in an increased 
chance of the retained products being expelled spontaneously.  Salim et al., 
(2004) have subsequently found that women at high risk of miscarriage have 
higher level of IGFBP-1 in uterine flushings from peri-implantation endometrium, 
suggesting that abnormal trophoblast invasion may be a mechanism for 
pregnancy loss in these women.  
IGFBP-1 is also being investigated as a marker of obstetric complications.  Low 
levels of IGFBP-1 in cervical secretions are associated with a low-risk of pre-
term delivery (Balic et al., 2008) and IGFBP-1 genes have been found to be 
upregulated in IUGR placentas (Okamoto et al., 2006).  
 
2.1.3  Ultrasound in early pregnancy 
High resolution transvaginal ultrasonography (TVS) is now the method of choice 
when assessing early pregnancy and has been shown to be superior to 
transabdominal ultrasound in diagnostic accuracy (Cacciatore et al., 1989) and 
the use of TVS has revolutionised the management of early pregnancy 
problems.  Recent RCOG guidelines recommend that all early pregnancy 
assessment units (EPAUs) should have access to TVS with staff appropriately 
trained in its use (RCOG, 2006).  
The gestational sac is the first pregnancy structure that can be detected by 
ultrasound.  It is usually visualised from 4+3 weeks gestation onwards when it 
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measures 2-3 mm in diameter (Yeh et al., 1986).  The gestational sac includes 
the chorionic cavity, a rim of invading chorionic villi and the underlying decidual 
reaction.  It is usually located eccentrically in the upper part of the uterine cavity 
and grows approximately 1 mm in diameter per day changing its shape from 
being round (up to 1 cm in size) to more elliptical thereafter.  The early 
gestational sac contains two separate fluid filled compartments: the amniotic 
and exocoelomic (chorionic) cavity.  In very early pregnancy the exocoelomic 
cavity predominates.  From 8 weeks the amniotic cavity expands rapidly and 
soon occupies most of the gestational sac.  By the end of the first trimester the 
amniotic and chorionic membranes fuse resulting in the complete obliteration of 
the exocoelomic cavity.  Normal ranges for gestational and amniotic sac size in 
early pregnancy have been established.  
The yolk sac is first seen during the fifth week as a circular, well-defined, echo-
free area within the gestational sac measuring 3-4 mm in diameter.  The yolk 
sac grows slowly until it reaches a maximum diameter of 6 mm at 10 weeks 
gestation (Jauniaux et al., 1991).  It is the yolk sac that plays a major role in the 
nutrition of the early embryo.  The yolk sac floats within the exocoelomic cavity 
and has been shown to have absorptive epithelia.  It is thought that nutrients of 
maternal origin absorbed by the trophoblast pass into the coelomic fluid and are 
absorbed by the yolk sac (Burton, Hempstock & Jauniaux, 2001).  
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Figure 3.  Gestational sac size correlated with menstrual age during the 
first 12 weeks (Nyberg et al., 1987).  
 
The embryo can first be demonstrated on TVS at the beginning of the sixth 
week, when it measures around 2 mm.  It is first seen as a straight echogenic 
line, adjacent to the yolk sac and close to the connecting stalk.  The cardiac 
activity begins at approximately day 37 (5+2 weeks) menstrual age (Bree et al., 
1989).  This corresponds to the crown-rump length of 1.5-3 mm.  When the 
embryo reaches 5 mm in length it can consistently be seen separate from the 
yolk sac and all embryos of that size should have visible cardiac activity.  This 
corresponds to 6+3 weeks gestational age and the sac diameter should measure 
15-20 mm.  The embryo grows at around 1 mm per day and the average crown-
rump length is 12 mm at 7+3 weeks and 20 mm at 9 weeks.  
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Gestation Key landmarks 
5 weeks Empty gestational sac (mean diameter 10 mm) 
5 ½ weeks Gestational sac with yolk sac visible 
6 weeks Gestational sac (mean diameter 16 mm) and yolk sac with 
adjacent heart beat but small embryo (3 mm) 
6 ½ weeks Embryo with crown-rump length of 6 mm with heart beat visible 
(rate 125 bpm) 
7 weeks Embryo with crown-rump length of 10 mm with heart beat 
visible (rate 150 bpm) 
8 weeks Embryo with crown-rump of 16 mm with separate amniotic sac 
and coelomic cavity with yolk sac.  Fetal body movements 
visible, heart rate 175 bpm.  
 
Table 1.  Key chronological landmarks in the development of the embryo, 
as seen on transvaginal ultrasound examination (Hately et al., 1995).  
 
2.2 EARLY PREGNANCY PROBLEMS 
2.2.1  Initial assessment 
Early pregnancy failure is a large burden on health services because of its high 
incidence and complex clinical management, which often requires the use of 
multiple diagnostic tests and in-patient surgical treatment.  Assessment of early 
pregnancy is indicated in women with clinical symptoms suggestive of 
miscarriage or ectopic pregnancy and in asymptomatic women who have 
experienced miscarriage in the past and those at high risk of ectopic pregnancy 
(Ankum et al., 1996).  Assessment tools include ultrasonography and 
measurement of biochemical markers (see Figure 4). 
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Figure 4.  Basic diagnostic algorithm for early pregnancy loss (RCOG 2006) 
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2.2.2 Pregnancy of Unknown Location   
Epidemiology and aetiology 
In 5-31% of patients presenting to an EPAU it may not be possible to confirm 
the pregnancy site by TVS at first visit (Banerjee et al., 2001; Hahlin et al., 
1995; Banerjee et al., 1999; Cacciatore et al., 1988).  A recent consensus 
statement (Barnhart et al., 2011) has emphasised the importance of 
consistency in the terminology used for the classification of these initial 
ultrasound findings.  The use of five categories is suggested: definite ectopic 
pregnancy, probable ectopic pregnancy, PUL, probable intrauterine pregnancy, 
and definite intrauterine pregnancy.  
Pregnancy of unknown location (PUL) is a descriptive term rather than a 
pathological diagnosis which describes when there is a positive pregnancy test 
but no evidence of an intrauterine or extrauterine pregnancy on TVS.  There are 
three possible diagnoses: a viable intrauterine pregnancy that is too small to 
see on TVS, a complete miscarriage where the pregnancy has already been 
lost, and an ectopic pregnancy.  Failing PULs (or trophoblast in regression) 
account for 44-69% of the PUL population (Hajenius et al., 1995; Banerjee et 
al., 2001) and are never visualised using transvaginal ultrasonography.  An 
indeterminate proportion of these represent complete miscarriages and self-
limiting forms of ectopic pregnancies (Condous et al., 2006).  
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 Number 
of 
cases 
Failing 
PULs 
(%) 
Normal 
IUPs 
(%) 
Miscarriage 
(%) 
Ectopic 
Pregnancy 
(%) 
Hajenius et 
al., 1995 
265 44 31 26 
Banerjee et 
al., 1999 
127 50 27 9 14 
Banerjee et 
al., 2001 
104 69 22 2 7 
Condous et 
al., 2005 
527 57 34 
 
 
Facey et al., 
2006 
74 69 9.5 9.5 12 
 
Table 2. Comparison of PUL final outcomes 
 
Biochemical markers 
Serial measurements of serum hCG are often used in the assessment of 
pregnancies of unknown location and a large number of women are subjected 
to invasive diagnostic procedures.  An ectopic pregnancy is “diagnosed” if the 
hCG does not double in 2-3 days as seen in normal intrauterine pregnancies.  
This approach is based on the assumption that all ectopic pregnancies follow 
the same abnormal development pattern, however as many as 10% of ectopics 
develop in the same way as normal intrauterine pregnancies.  In addition, a 
large proportion of ectopics are failing pregnancies, similar to the miscarriage of 
an intrauterine pregnancy.  An abnormal doubling time is therefore neither a 
sensitive nor specific method for diagnosing ectopic pregnancies (Shepherd et 
al., 1990).  Another approach used to diagnose ectopic pregnancy is the use of 
a serum cut-off level above 1000 IU/L of hCG at which point a normal, 
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intrauterine pregnancy should be seen by transvaginal sonography (Cacciatore 
et al., 1990).   
Lower levels of hCG in pregnancies that are destined to fail have been well 
documented.  As hCG production is directly related to the amount of trophoblast 
present it has been suggested that suboptimal serial changes in hCG may be a 
more accurate marker of trophoblast viability.  
Recently a number of diagnostic models for prediction of resolution of 
pregnancies of unknown location have been suggested.  In 1995, Hahlin et al. 
used a combination of serum progesterone and serial hCG measurements to 
predict safe expectant management.  If the serum hCG change was less than 
5% and the progesterone less than 20 nmol/L then the sensitivity of the model 
was 73% and the specificity 97%.  In 1999, Banerjee et al., developed a logistic 
regression model using the biochemical markers hCG and progesterone along 
with endometrial thickness and the presence of bleeding.  This model had a 
sensitivity and specificity of 92% in identifying failed pregnancies undergoing 
spontaneous resolution.  Prospective evaluation of both models by Banerjee et 
al., in 2001 however, showed that using a serum progesterone of less than 20 
nmol/L was as accurate as either model (see Figure 5).  
The use of hCG ratios (hCG 48 hours/hCG 0 hour) in the prediction of 
spontaneous resolution of pregnancies of unknown location (PULs) has recently 
been assessed in a prospective cohort study (Condous et al., 2006).  An hCG 
ratio of <0.87 was found to outperform absolute serum hCG levels with a 
sensitivity of 92.7% and a specificity of 96.7%.  Unfortunately there has not yet 
been any valid comparison of hCG ratios versus the use of initial hCG with 
progesterone to suggest which model is more efficacious and cost effective.  A 
recent prospective observational study has looked at hCG ratio versus 
progesterone in women with PUL (Bignardi et al., 2010).  This study looked at 
prediction of viability once an IUP was detected at follow-up scan, and not PUL 
outcome.  HCG ratio was found to perform only slightly better than a single 
serum progesterone (area under ROC curves 0.756 and 0.678 respectively).  
Expectant management of PULs has been shown to be safe, reduce the need 
for unnecessary surgical intervention and is not associated with serious adverse 
outcomes (Condous, Okaro & Bourne, 2003).  Nevertheless, 9-29% of women 
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will require surgical intervention due to a worsening clinical condition or non-
declining hCG (Hahlin, Thorburn & Bryman, 1995; Banerjee et al., 1999).   
 
 
 
 
Figure 5.  Receiver Operating Characteristics curves demonstrating the 
performance of Hahlin's and the logistic regression model, serum 
progesterone, serum β-hCG and endometrial thickness in their ability in 
predicting correctly which pregnancies will resolve without the need for 
any intervention (Banerjee et al., 2001).  
 
2.2.3  Miscarriage 
Epidemiology and aetiology 
A miscarriage is an intrauterine pregnancy that ends spontaneously before the 
fetus has reached viability.  This is currently defined by the World Health 
Organisation as the spontaneous expulsion from its mother of a fetus weighing 
less than 500 g or before 24 weeks of gestation.  A missed miscarriage is 
defined as an anembryonic pregnancy or where there is early fetal demise but 
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the gestational sac remains in utero.  An incomplete miscarriage is one where 
part but not all of the products of conception have been passed from the uterus.  
A complete miscarriage is one where all of the products of conception have 
been passed and the uterus is now empty.  
Miscarriage is the most common complication of early pregnancy.  It has been 
estimated that the overall miscarriage rate is around 40% (Wang et al., 2003).  
The majority of these losses occur before the missed menstrual period but 
bleeding complicates 21% of clinically detected pregnancies and 12-15% are 
lost (Kline et al., 1989; Nybo Anderson et al., 2000).  Miscarriage accounts for 
50000 inpatient admissions to hospitals in the UK annually (Bradley & Hamilton-
Fairley, 1998).  
Failure of spiral artery transformation and inadequate placentation is important 
in spontaneous miscarriage (Haxton & Bell 1983; Gaillard et al., 1993).  Khong 
et al. (1987) and Hustin, Jauniaux & Schaaps (1990) both showed that by 
examining the histological specimens of spontaneous miscarriages, defective 
transformation of the spiral arteries, and a reduced trophoblastic infiltration of 
the decidua could be seen.  Colour Doppler studies have shown that at 7-12 
weeks of gestation a high resistance to flow in decidual arteries is associated 
with up to a 43% risk of subsequent miscarriage (Jaffe & Warsof, 1992).  
Jauniaux et al. (1994) found that in missed miscarriages the trophoblastic shell 
was thinner and discontinuous, and that the intervillous space and endometrium 
were massively infiltrated with blood.  They suggest that this is due to reduction 
or absence of vascular plugs allowing free access of blood to the intervillous 
space with subsequent arrest of embryoplacental flow, or retroplacental 
haemorrhage and abruption.  The mechanical cause of most miscarriages is 
thought to be this premature entry of maternal blood into the intervillous space.  
The low oxygen state of the early placenta would appear to be necessary for 
the differentiation of the trophoblast, angiogenesis and protein synthesis and 
increasing the oxygen flow to the intervillous space would appear to be a factor 
in early pregnancy failure (Jauniaux et al., 2000).   
 24 
 
A woman may present at various stages of the process of miscarriage.  
Ultrasound classification of miscarriages has superseded clinical classification, 
which was based on the amount of bleeding and the state of the internal 
cervical os on examination (see Figure 6).  
 
 
 
 
 
 
 
 
 
 
Figure 6.  Natural course of miscarriage, with opportunities for 
intervention as illustrated by Ankum et al., (2001).  
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Ultrasound findings on initial scan Action required 
Gestational sac of mean diameter >20 mm with no 
evidence of an embryo or yolk sac  
Repeat scan in one 
week 
Crown-rump length >10 mm with no heart action Repeat scan in one 
week 
Gestational sac <15 mm or crown-rump length <10 
mm 
Repeat scan in two 
weeks 
 
Table 3.  Guidelines for establishing the death of an embryo by ultrasound 
(Hately et al., 1995) 
 
Biochemical markers 
Biochemical markers have been used to predict early pregnancy outcome.  A 
number of small studies have also shown low levels of progesterone in 
nonviable pregnancies (see Table 4) and a progesterone level of less than 25 
nmol/L in an anembryonic pregnancy has been shown to be diagnostic of 
nonviability (see Table 5).   
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Authors Diagnosis Cut-off level of 
progesterone for 
viability (nmol/L) 
Specificity 
Hahlin, Sjoblom & 
Lindblom (1991) 
Miscarriage/ectopic 30 nmol/L 77% 
Cunningham et al., 
(1993) 
Asymptomatic 
Symptomatic 
45 nmol/L 
30 nmol/L 
91% 
94% 
Stewart, Nazar-
Stewart & Toivola 
(1995) 
Miscarriage/ectopic 24 nmol/L 88% 
Aksoy et al., (1996) Miscarriage 36 nmol/L 90% 
 
Table 4.  Comparison of the cut-off levels of progesterone used in the 
diagnosis of early pregnancy failure 
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Authors Cut-off level of 
Progesterone for 
viability (nmol/L) 
Specificity  Sensitivity 
Riss et al., (1989) 48 nmol/L 83% 87% 
Elson et al., (2003) 25 nmol/L 40% 100% 
 
Table 5.  Comparison of the cut-off levels of progesterone used in the 
diagnosis of viability in anembryonic pregnancy 
 
Studies have demonstrated the variable expression of a single glyco-isoform of 
hCG in early successful and failed pregnancies.  These studies use specific 
antibodies to C5 hCG (monoclonal antibody B152) which is a hyperglycosylated 
structure related to choriocarcinoma hCG.  Relatively high levels of this isoform 
hyperglycosylated hCG (H-hCG) have been described in the first 5-6 weeks 
gestation, with a subsequent decline in expression as pregnancy progresses 
but which persists in failing pregnancy (Sutton Riley et al., 2006).  Whether over 
expression of H-hCG is an isolated phenomenon or is associated with variable 
expression of other isoforms is not known.   
 
Management 
Diagnosis of miscarriage has traditionally been followed by surgical curettage, 
on the assumption that this decreases the risk of subsequent gynaecological 
infection.  Surgical management is not, however, without complications (Chung 
et al., 1999) and a recent randomised control trial has shown that the incidence 
of gynaecological infection after first trimester miscarriage is low (2-3%) and 
does not differ by the method of management (Trinder et al., 2006).  Surgical 
evacuation does remain the treatment of choice if endometrial thickness is >50 
mm, bleeding is excessive, vital signs are unstable or infected tissue is present 
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in the uterine cavity (in which case surgery must be performed with antibiotic 
cover) (Sagili & Divers, 2007).  Fewer than 10% of women who miscarry fall into 
these categories (Ballagh et al., 1998).   
Alternative management options include medical management and expectant 
management.  Medical management uses drugs to aid expulsion of retained 
products.  It is the preferred choice of women over surgical management 
(Demetroulis et al., 2001), and there are cost savings (Petrou et al., 2006).  
Trials have reported widely varying success rates, from 13% to 93% (De Jonge 
et al., 1995; Sahin et al., 2001).  Comparisons are limited by the use of different 
drug regimens and different measures of success.  No statistical difference in 
efficacy has been shown between surgical and medical management in 
incomplete miscarriage (Muffley et al., 2002) and in women with incomplete 
miscarriages medical treatment has not been shown to offer any benefits over 
expectant management (Nielsen, Hahlin & Platz-Christensen, 1999).  
Expectant management follows the natural history of the condition, allowing the 
spontaneous passage of retained products of conception.  It avoids the 
iatrogenic problems associated with both medical and surgical treatment and is 
the most cost-effective (Petrou et al., 2006).  In incomplete miscarriage 
expectant management has been shown to be very effective.  Luise et al., 
(2002) showed a 91% success rate and Nielsen & Hahlin (1995) found that 
expectant management resulted in complete uterine evacuation over three days 
in 79% of cases of incomplete miscarriage.  Efficacy was reduced to 37% after 
seven days when expectant management was used to treat women with 
miscarriage mostly diagnosed as early fetal demise (Wieringa-de Waard et al., 
2002).  A recent prospective observational study has shown that after just 2 
weeks of expectant management, spontaneous resolution had occurred in 71% 
of incomplete miscarriages, 53% of “empty sacs” and 35% of missed 
miscarriages (Casikar et al., 2010).  
Attempts have been made to determine parameters which predict the success 
of expectant management.  Schwarzler et al. (1999) examined 108 patients with 
missed miscarriages, of which 78 underwent expectant management.  They 
used colour Doppler to examine the intervillous blood flow and found that those 
with intervillous blood flow were more likely to undergo spontaneous 
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miscarriage than those without.  By examining the patients’ characteristics with 
logistic regression analysis, they showed that both hCG and progesterone were 
able to predict spontaneous miscarriages.  However only progesterone was 
statistically significant.  Nielsen, Hahlin & Oden, (1996) designed a logistic 
regression model to identify women with first trimester spontaneous 
miscarriages suitable for expectant management.  They used data from 103 
women undergoing expectant management of incomplete miscarriages of which 
81 completed spontaneously and 22 went on to have surgical management.  
Those patients who miscarried completely were more likely to have lower serum 
progesterone, 17-OHP, and hCG levels.  They also had a significantly smaller 
intrauterine diameter of retained products of conception.  They created a logistic 
regression model involving progesterone, hCG and intrauterine diameter 
measured by ultrasound scan.  This model had a 98% positive predictive value 
(PPV) and 44% negative predictive value (NPV) for the probability that no more 
than 2% of women would undergo surgical management, and a 90% PPV and 
67% NPV that 80% of the women with the highest probability of complete 
miscarriage were managed expectantly.  The time limit allowed for expectant 
management was only three days.  A recent study of 54 women (Elson et al., 
2005a) has shown that by using some of these markers (including IGFBP-1, 
inhibin A, and inhibin pro αC) they could predict the appropriate management 
for 81% of women with miscarriages (see Figure 7).  These data need to be 
confirmed to ensure that it is appropriate for general clinical use.  
 
 30 
 
Figure 7.  Decision tree analysis for expectant management of miscarriage 
(Elson et al., 2005a) 
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2.2.4  Ectopic pregnancy 
Epidemiology and aetiology  
An ectopic pregnancy is defined as implantation of the fertilised ovum outside 
the uterine cavity.  In the UK during the period 2006-2008 more than 35000 
ectopic pregnancies were estimated to have occurred and there were 6 
maternal deaths resulting from ectopic pregnancy (CMACE, 2011).  This rate 
has declined since the last triennial report and is the lowest since figures were 
first estimated in 1988.  Whether this is a trend or an anomaly remains to be 
seen. 
The majority of ectopic pregnancies (95%) are tubal in origin while a small 
proportion may be interstitial, primary abdominal, ovarian or cervical.  80% of 
tubal ectopics are located in the ampullary segment of the tube (Wong & Clark, 
1968).  The clinical presentation is very variable.  Diagnosis of all women at risk 
for ectopic pregnancy should be prompt but it is not always an emergency.  A 
haemodynamically stable woman should be diagnosed before rupture, a goal 
that can usually be accomplished without laparoscopy.  For women who present 
in shock, immediate surgery is both diagnostic and therapeutic (ASRM, 2006).  
Kemp et al., (1999) suggested that the placentation could be the key factor in 
the difference between viable and nonviable tubal pregnancies.  They 
compared the histology in these two groups and found that the viable ectopic 
pregnancies were more likely to be implanted on the mesosalpingial side of the 
tube, that they had deeper trophoblastic invasion and that they had increased 
villous vascularisation.   
Factors with a proven role in increasing the risk of ectopic pregnancies include 
previous ectopic pregnancy and previous tubal surgery, tubal pathology, in 
utero diethylstilboestol exposure, previous pelvic inflammatory disease, 
pregnancy after sterilisation and with intrauterine contraceptive device (IUCD) in 
situ, and smoking (Marchbanks et al., 1988; Ankum et al 1996; Bouyer et al., 
2003).  In theory an abnormal conceptus could be predisposed to ectopic 
implantation due to delayed migration but studies have not confirmed an 
important role for chromosomal abnormalities in the aetiology of ectopic 
pregnancies (Goddijn et al., 1996).  
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Biochemical markers 
Biochemical markers have been used both to diagnose ectopic pregnancy and 
in its management.  Abnormal implantation leads to reduced levels of βhCG 
being seen in ectopic pregnancies.  Traditionally an ectopic pregnancy is 
diagnosed if the hCG does not double in 2-3 days as seen in normal intrauterine 
pregnancies.  However, this may also be the case in a failing intrauterine 
pregnancy.  An abnormal doubling time is neither sensitive nor specific method 
to diagnose ectopic pregnancy (Shepherd et al., 1990).  Another approach used 
to diagnose ectopic pregnancy is a serum cut-off level above 1000-1500 IU/L of 
βhCG at which point an intrauterine pregnancy should be seen by transvaginal 
sonography.  However this fails to take into account the time to return to normal 
of serum βhCG levels following miscarriage or the diagnostic accuracy of 
ultrasound in the presence of uterine anomalies such as fibroids (Barnhart et 
al., 1999).  The serum level of hCG would appear to be higher in those women 
with deeper trophoblastic invasion into the tubal wall than in those where the 
ectopic trophoblast is limited to the lumen or tubal mucosa (Natale et al., 2003).  
Several studies have demonstrated reduced progesterone and 17-OHP levels 
in ectopic pregnancies (Hahlin et al., 1991; Choe et al., 1992; Stewart et al., 
1995).  This is thought to be due to abnormal implantation thus affecting the 
luteal-placental axis (Sauer et al., 1988).  Progesterone and βhCG may 
therefore be used together with ultrasound for the diagnosis and management 
of pregnancies of unknown location as these pregnancies are likely to resolve 
spontaneously regardless of location (Banerjee et al., 1999).  
Only one small study has assessed the value of more novel biochemical 
markers in the diagnosis of ectopic pregnancy.  Illingworth et al., (1996) 
examined eight women with ectopic pregnancies and compared their inhibin A 
and pro-αC-RI levels with levels of eight women with ongoing intrauterine 
pregnancies.  There was no significant difference between the two groups.   
 
Ultrasound 
Traditionally the findings of a positive pregnancy test and an empty uterus seen 
at the time of ultrasound scan have been synonymous with the presence of an 
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ectopic pregnancy.  However with the use of transvaginal ultrasound, 
approximately 85% of ectopic pregnancies can be visualised directly (Ofili-
Yebovi et al., 2003) and so transvaginal ultrasound has become the single 
diagnostic tool of choice for ectopic pregnancy.  Like laparoscopy, ultrasound 
does not confer 100% sensitivity for the diagnosis of tubal ectopic pregnancy, 
however it is safe, inexpensive and non-invasive, is acceptable by women and, 
in trained hands, is highly reproducible (Condous, 2007).   
The following transvaginal ultrasonagraphic criteria are used for the diagnosis of 
ectopic pregnancy: (1) an inhomogenous adnexal mass (“blob sign”) (Condous 
et al., 2005); (2) an empty extrauterine sac with a hyperechoic ring (“bagel-
sign”) (Goldstein & Timor-Tritsch, 1995); and (3) a yolk sac of fetal pole with or 
without cardiac activity in an extrauterine sac.  Recent studies using high-
resolution sonography have shown the most common morphology to be a solid 
ectopic pregnancy (Elson et al., 2000) and in a meta-analysis of ten studies, a 
non-cystic adnexal mass or an inhomogenous mass was diagnostic of an 
ectopic pregnancy with a sensitivity and specificity of 84.4% and 98.9% 
respectively (Brown & Doubilet, 1994).  
 
Management 
There are three main methods of currently managing an ectopic pregnancy: 
surgical, medical and expectant.  Surgical management is indicated in all 
haemodynamically unstable patients and in selected other cases.  Surgical 
options include salpingectomy or salpingostomy, done either as an open 
procedure or laparoscopically.  Three randomised trials have shown that 
laparoscopy is superior to laparotomy in haemodynamically stable patients 
(Vermesh et al., 1989, Lundroff et al., 1991, Koninckx et al., 1991).  
The folic acid antagonist methotrexate has been widely used for the medical 
treatment of ectopic pregnancies since the late 1980s.  Methotrexate inhibits 
dihydrofolate reductase and so prevents the reduction of folic acid to 
tetrahydrofolate, a key step in the synthesis of DNA and RNA precursors.  
Methotrexate therefore leads to interference with DNA synthesis and cell 
multiplication in the conceptus.  It can be given either intramuscularly or by 
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direct injection into the ectopic pregnancy, either laparoscopically or under 
ultrasound guidance.  In the UK methotrexate is most commonly given as a 
single intramuscular dose of 50 mg/m2.  Single dose regimens have reported 
success rates varying from 64-94% (Stovall & Ling, 1993, Stika et al., 1996).  
Methotrexate treatment is more likely to be successful if the initial hCG level is 
low.  Ransom et al., (1994) also showed that ectopic pregnancies with serum 
progesterone <10 nmol/L are more likely to be successfully treated by systemic 
methotrexate injection.  
It is now well recognised that not all ectopic pregnancies require treatment as 
some will resolve spontaneously.  Expectant management is becoming 
increasingly important as the ability to detect small ectopic pregnancies and 
tubal miscarriages increases.  It is important that the ectopic pregnancy is 
actually visualised to avoid mistakenly managing expectantly live or large 
ectopic pregnancies where the risk of failure is high.   
Large multicentre randomised controlled trials are currently underway in the UK 
and Netherlands (The METEX study, van Mello et al., 2008) to compare 
methotrexate and expectant management in haemodynamically stable patients 
with an ectopic pregnancy and low serum hCG or PUL with low but plateauing 
hCG concentrations.  Results and guidance from these ongoing studies are 
eagerly awaited.    
Studies show that around a quarter of ectopic pregnancies will be suitable for 
expectant management (Ylostalo et al., 1992; Elson et al., 2004).  The selection 
criteria for expectant management varies but those ectopic pregnancies with a 
viable fetus or the presence of haemoperitoneum would be considered 
unsuitable for all but surgical management.  In expectant management once the 
ectopic pregnancy is diagnosed management varies but consists of follow-up 
with a combination of serial ultrasound scans, hCG and progesterone 
measurements.  The hCG levels are monitored until they drop below 20 IU/L 
indicating spontaneous resorption of the pregnancy.  An increase in the size of 
the ectopic pregnancy or a rise in the serum hCG levels would be an indication 
to consider surgery.    
Success rates for expectant management vary between 50-100% (Lund, 1955; 
Sauer et al., 1987).  Several attempts have been made to examine the clinical, 
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ultrasound and biochemical parameters that can predict the success of 
expectant management.  Fernandez et al., (1988) looked at 14 patients with 
ectopic pregnancies confirmed by laparoscopy.  64% of these resolved 
spontaneously.  This study found that a serum hCG below 1,000 IU/L appeared 
to be the best marker for successful expectant management.  Garcia et al., 
(1987) reported on 13 women with ectopic pregnancies of less than 4cm in size 
diagnosed at laparoscopy.  Only one case required surgical intervention.  They 
found that serum βhCG, progesterone and oestradiol levels were all below the 
ranges expected for normal pregnancies but did not describe any threshold 
levels.  Shalev et al., (1995) examined 60 women with laparoscopically 
diagnosed ectopic pregnancies.  They found that the presenting level of hCG, 
the rate of fall of hCG and the size of the ectopic pregnancy at laparoscopy 
were significant factors in predicting successful expectant management.  They 
suggested that using a presenting level of hCG of <2,000 IU/L allowed a 60% 
success rate.   
Ylostalo et al., (1992) examined 83 patients, which represented 26% of all their 
ectopic pregnancies over a 2-year period.  They found that around 69% of the 
83 cases, or 18% of all ectopic pregnancies, resolved spontaneously.  They 
also used 4 cm as a cut-off for the size of the ectopic pregnancy and included 
those ectopic pregnancies with a fetal pole and no fetal heartbeat.  Whilst they 
also found that the hCG levels were significantly higher in the group with failed 
expectant management than those who finally resolved spontaneously, there 
were cases with high initial values with successful expectant management.  No 
attempt to define whether the morphology of the ectopic pregnancies 
contributed to the final outcome was examined.  
Sauer et al., (1987) compared the biochemical profiles of spontaneously 
resolving ectopics, viable ectopics and normal intrauterine pregnancies.  They 
found that hCG, progesterone, 17-OHP, and oestradiol were all significantly 
lower in ectopic pregnancies.  By using a low threshold for progesterone of 4 
nmol/L, they found that the ectopic pregnancies with progesterone below this 
level had a shorter time to resolution.  There was a high degree of correlation 
between 17-OHP and progesterone.  The fall in progesterone and 17-OHP 
preceded the fall in hCG levels by 7-29 days.  
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Cacciatore et al., (1995) examined the sonographic findings and hCG levels in 
expectantly managed ectopic pregnancies.  They found that 69% of 71 patients 
had spontaneously resolving ectopic pregnancies.  They concluded that whilst 
initial hCG and size of the ectopic pregnancy did not differ between the two 
groups, a decrease in the size of the ectopic pregnancy by day 7 was a 
significant predictor.  
Elson et al., (2004) found significant differences in demographic, ultrasound and 
biochemical findings between spontaneously resolving ectopics and those 
requiring treatment.  They devised a decision tree that may be used as a guide 
to estimate the probability of successful expectant management in individual 
cases (see Figure 8).  This could predict outcome with a probability of 88% in 
five out of the seven subgroups, which accounted for 69% of the study 
population.  As novel biochemical markers have been shown to be more 
accurate indicators of the luteal-trophoblastic axis (Elson et al., 2005a) it is likely 
that they may be useful for predicting the spontaneous resolution of ectopic 
pregnancies more accurately.    
Fertility rates after expectant management have been examined and patients 
treated in this way have good long-term fertility outcomes with spontaneous 
pregnancy rates of around 80% (Carp et al., 1986).  The risk of repeat ectopic 
pregnancies is low, around 4%.  
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Figure 8.  Schematic representation of the decision tree analysis 
employed in the study for the expectant management of tubal ectopic 
pregnancy (Elson et al., 2004). 
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2.3 SUMMARY 
It is clear from the literature review presented that the management of early 
pregnancy problems has benefited from the introduction of transvaginal 
ultrasound scanning and the adjunctive use of biochemical markers.  We have 
also identified a number of areas in need of further research to improve our 
understanding of the pathophysiology of early pregnancy failure and to improve 
the care received by patients with early pregnancy problems.  Our research 
questions include is the glycosylation of hCG involved in early pregnancy 
failure?  Can the successful expectant management of miscarriage and failed 
pregnancies be predicted using novel biochemical markers as described by 
Elson et al., (2005a, 2005b) in our own population?  And will these biochemical 
markers similarly predict the successful expectant management of pregnancies 
of unknown location?  
The original research presented endeavors to answer these questions.  The 
glycosylation of hCG and expectant management studies were conceived 
separately and are not related apart from in their overarching theme ‘the use of 
novel biochemical markers in the diagnosis and management of early 
pregnancy problems’.     
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CHAPTER 3.  MATERIALS AND METHODS 
3.1 PATIENT RECRUITMENT 
Patients for these prospective observational studies were recruited from the 
Early Pregnancy Assessment Unit of Sunderland Royal Hospital during the 
period August 2005 and June 2008.  The Unit serves a local community of 
330,000 residents including both inner city and rural areas with a high level of 
socio-economic deprivation.  This is a secondary referral unit seeing 
approximately 1300 women per year.  Women can be referred by their midwife, 
general practitioner, accident and emergency department, family planning 
department or hospital doctor if they have pain or bleeding in early pregnancy.  
The unit also has an open access policy for women who have had a previous 
ectopic pregnancy or two previous miscarriages.   
Patients were also recruited from the Early Pregnancy Assessment Unit of 
King’s College Hospital, London, for the pregnancy of unknown location and 
ectopic pregnancy studies, during the period August 2006 and July 2007.  The 
Unit serves a racially mixed inner city population with a high level of socio-
economic deprivation.  This is a tertiary referral unit seeing approximately 2,500 
women per year.  The unit has an open access policy and additionally sees 
women referred by their general practitioner or hospital consultants. 
In both units all women are triaged by a nurse and if appropriate undergo a 
urine pregnancy test (Clearview HCG IITM, Unipath, Bedford, UK).  This test is a 
monoclonal antibody test which according to the manufacturers specifications 
has a sensitivity of 99% at a urine β-hCG level greater than 25 IU/L.  Those 
women with a positive test then undergo ultrasound scanning and biochemical 
testing as appropriate.   
Clinically stable women with an ultrasound diagnosis of pregnancy of unknown 
location, missed or incomplete miscarriage, or ectopic pregnancy, who were 
suitable for and chose expectant management were eligible to take part in the 
expectant management studies.   
Informed written consent was taken from all women prior to inclusion in the 
studies. 
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3.2 ETHICS COMMITTEE APPROVAL 
Approval for recruitment of women into the glycosylation of hCG study was 
granted by Sunderland Local Research Ethics Committee (SLREC 704) and for 
the expectant management studies by Northumberland Regional Ethics 
Committee (05/Q0902/63).   
 
3.3 ULTRASOUND 
3.3.1 Ultrasound Equipment 
The equipment used at Sunderland Royal Hospital was a Toshiba Powervision 
6000, with a Toshiba IPVM-651VT 6MHz transvaginal probe (Toshiba Medical 
Systems Ltd, Tokyo, Japan) when a TVS was indicated. The equipment used at 
King’s College Hospital was an Aloka ultrasound system with a 5MHz 
transvaginal probe. (Aloka SSD-5000, Aloka Co. Ltd, Tokyo, Japan). The 
mechanical index (MI) was continuously displayed during examination and it 
was always kept <1. 
 
3.3.2 Ultrasound Method 
Ultrasounds were performed by sonographers and verbal consent for the 
procedure was obtained in all cases.  In accordance with departmental 
guidelines initial scans were performed transabdominally when the estimated 
gestational age was nine weeks or greater, and transvaginally when less than 
nine weeks.  Transvaginal scans were performed following transabdominal 
scans when required.  The bladder was emptied prior to transvaginal scanning.  
The probe was introduced gently into the vagina and the cervix and uterus 
demonstrated in the sagittal plane.  The probe was then rotated through 90o and 
the uterus examined in the coronal plane from fundus to the cervical region.  
Whilst in the coronal plane the tip of the probe was tilted to the patients right 
and the right ovary and adnexa examined in the coronal and sagittal planes.  
The tip of the probe was then tilted to the other side and the left ovary and 
adnexa then examined in the same way.  Finally the pouch of Douglas was 
inspected for the presence of free fluid.   
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3.3.3 Ultrasound measurements 
All measurements were done on a frozen ultrasound image with callipers.  The 
endometrial thickness was measured from a longitudinal image through the 
thickest area of the endometrium, from the outermost border of the 
endometrium on one side to that on the other side.   
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Figure 9.  Longitudinal ultrasound image of the uterus, with the 
measurement of endometrial thickness from outermost border of the 
endometrium on one side to the other (image courtesy of J. Elson) 
 
 
In the case of an incomplete miscarriage, the intrauterine diameter of the 
retained products of conception was determined by taking two further 
measurements in the coronal plane at the thickest area and calculating the 
diameter as endometrial thickness x diameter 2 x diameter 3 divided by 3. 
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Figure 10.  Ultrasound measurement of retained products of conception – 
longitudinal section (Endometrial thickness 22.5 mm) 
 
Tubal ectopic pregnancies were diagnosed only when there was an adnexal 
mass with morphological characteristics of an ectopic separate to the ovary and 
corpus luteum.  For ectopic pregnancies the average diameter of the ectopic 
pregnancy was calculated by measuring the ectopic pregnancy in three 
dimensions.   
The morphology of the ectopic pregnancy was classified into four categories: 
gestational sac with an embryo, gestational sac with a yolk sac, gestational sac 
with no detectable embryonic structures and homogenous or solid tubal mass.   
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Figure 11.  Ultrasound measurements of an ectopic pregnancy showing a 
solid left sided tubal mass 
 
Measurements of intrauterine contents in missed miscarriages or normal 
pregnancies are demonstrated in Figure 12. 
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Gestational (chorionic) sac - Measurements should be 
performed from the inner edges of trophoblast in three 
planes.  The diameters measured correspond to those of the 
chorionic cavity.  The maximum and mean diameters 
should be recorded.  The volume is calculated 
using formula for ellipsoid 
V=AxBxCx 0.523. 
Amniotic sac - The three perpendicular diameters should 
be measured and the mean diameter calculated.  As the 
amnion is very thin the measurements should be taken 
from the centre of the membrane. 
 
Yolk sac - Three diameters are measured from the outer 
wall of the yolk sac. 
      Crown- rump length - In early pregnancy this is the 
greatest length of the embryo as the crown and rump 
cannot be distinguished.  From 7 weeks onwards the  
      measurement should be taken in the sagittal section, with 
care taken not to include the yolk sac.   
 
 
Figure 12.  Schematic representation of measurement of ultrasound 
images of early pregnancy showing gestational sac (GS), yolk sac (YS), 
amniotic sac (AS) and fetal pole (FP) (diagram courtesy of J. Elson) 
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P 
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Diagnosis of miscarriages were made in accordance with departmental 
guidelines as outlined in Table 6.  
 
The diagnosis of miscarriage can be made if ultrasound demonstrates one of 
the following: 
• Retained products of conception (>15 mm AP diameter) 
• Gestation sac >20 mm (mean sac diameter) with no contents or fetal 
pole 
• Fetal pole >10 mm with no fetal heart pulsation 
• No change in 2 scans with intrauterine pregnancy over 10 days 
 
Table 6.  Diagnostic criteria for diagnosis of miscarriage from CHS trust 
protocol ‘Management of Miscarriage’ 
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Figure 13.  Ultrasound picture of a missed miscarriage with no change in 
two scans over 10 days 
 
3.4 BIOCHEMISTRY 
Blood samples were collected in plain tubes.  All blood samples were 
centrifuged for 10 minutes at 1,000 RPM at room temperature and the serum 
extracted and frozen at -20oC.  The hCG and progesterone assays for those 
patients with either pregnancies of unknown location or ectopic pregnancies 
were measured immediately.  All others samples were frozen for later analysis 
in batches.   
The panel of novel biochemical markers was chosen to reflect all aspects of the 
luteo-trophoblastic unit.  Progesterone, inhibin pro-αC and 17-OHP are 
products of and reflect the function of the corpus luteum.  hCG is the major 
product trophoblast and IGFBP-1 is secreted by the decidua.  Inhibin A is 
produced both by the trophoblast and the corpus luteum. 
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3.4.1 hCG assay 
Serum hCG concentrations (intact hCG plus the hCG β-subunit) were quantified 
using an automated immunoassay technique and expressed in IU/L using the 
World Health Organisation Third International Reference 75/537.  For the 
glycosylation of hCG study the analysis was carried out using the Immulite 2000 
(Diagnostic Products Corporation, Los Angeles, CA, USA).  For the expectant 
management studies the analysis was carried out using the Roche E170 
(Roche Diagnostics, Mannheim, Germany) analyser at Sunderland Royal 
Hospital and the Bayer Immuno1TM (Bayer Diagnostics, Basingstoke, UK) was 
used at King’s College Hospital. 
Immulite 
Immulite hCG is a solid-phase, two site, chemiluminescent enzyme 
immunometric assay designed for the quantitative measurement of hCG in 
serum.  
o 5 µL of sample, reagent (alkaline phosphatase conjugated to polyclonal 
ovine anti-hCG in buffer) and beads are added together and incubated 
for 30 minutes. 
o Reagent is removed from beads by spinning the reaction tube at high 
speed along its vertical axis. 
o Beads are washed then chemiluminescent substrate is added. 
o The light emitted is detected at 477 nm by a photomultiplier tube. 
The inter and intra assay coefficients of variation are less than 10%. 
Roche E170 
 The test principle is a competitive immunoassay using two incubations.   
o 1st incubation: 30 µL of sample, biotinylated monoclonal hCG-specific 
antibodies, and a monoclonal hCG specific antibody labelled with a 
ruthenium complex react to form a sandwich complex. 
o 2nd incubation: after addition of streptavadin-coated microparticles the 
complex becomes bound to the solid phase via interaction of biotin and 
streptavadin. 
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o The reaction mixture is aspirated into the measuring cell where the 
microparticles are magnetically captured onto the surface of the 
electrode.  Unbound substances are then removed with ProCell.  
Application of a voltage to the electrode then induces chemiluminescent 
emission which is measured by a photomultiplier. 
o Results are determined via a calibration curve which is instrument-
specifically generated by 2-point calibration and a master curve provided 
via a reagent bar code. 
Bayer Immuno1 
The immunoassay technique used was a heterogenous sandwich magnetic 
separation assay (MSA).   
o The hCG antibody conjugate (R1) and the hCG antibody conjugate 2 
(R2) are reacted with the patient sample and incubated at 37 0C.   
o The monoclonal Immunomagnetic Particle (mIMP) reagent is added and 
a second incubation period occurs during which the antibody complex is 
bound.  The mIMP/antibody complex is then washed and the para-
nitrophenyl phosphate (pNPP) substrate is added.  The alkaline 
phosphatase (ALP) in the antibody conjugate reacts with the pNPP to 
form para-nitrophenoxide and phosphate.  Increasing absorbance due to 
formation of para-nitrophenoxide is monitored at 405 nm and 450 nm.   
o The dose/response curve will be directly proportional to the hCG 
concentration in the sample.   
The inter and intra assay coefficients of variation are less than 10%.  
A test series of 4 samples analysed at both sites (Sunderland Royal Hospital 
and King’s College Hospital) shows an 11% between-method variation (range 
0-17%). 
 
3.4.2 Progesterone assay 
Progesterone levels were quantified using an automated immunoassay and 
expressed in nmol/L.  At Sunderland Royal Hospital the analysis was carried 
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out using the Roche E170 (Roche Diagnostics, Mannheim, Germany) analyser  
and at King’s College Hospital the Bayer Immuno1TM (Bayer Diagnostics, 
Basingstoke, UK) was used. 
Roche E170 
The test principle is a competitive immunoassay using two incubations.   
o 1st incubation: 30µL sample – in the presence of a biotinylated 
monoclonal progesterone-specific antibody and a progesterone 
derivative labelled with ruthenium complex – are incubated with Danazol 
to release progesterone.  Progesterone from the sample competes with 
the labelled progesterone derivative for the antibody binding site. 
o 2nd incubation: After addition of streptavidin-coated microparticles, the 
complex becomes bound to the solid phase via interaction of biotin and 
streptavidin.  The amount of the labelled progesterone derivative bound 
to the solid phase is inversely proportional to the progesterone content of 
the sample. 
o The reaction mixture is aspirated into the measuring cell where the 
microparticles are magnetically captured onto the surface of the 
electrode.  Unbound substances are then removed with ProCell.  
Application of a voltage to the electrode then induces chemiluminescent 
emission which is measured by a photomultiplier. 
o Results are determined via a calibration curve which is instrument-
specifically generated by 2-point calibration and a master curve provided 
via the reagent barcode. 
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Bayer Immuno1 
The immunoassay method used is a heterogenous competitive immunoassay.   
o Anti-progesterone antibody (R1) is reacted with the patient sample and 
incubated at 37oC.   
o Progesterone enzyme conjugate (R2), which competes with the 
progesterone in the sample for binding sites on the antibody is then 
added followed by the mIMP.  A second incubation occurs during which 
the antibody/hapten complex is washed and the pNPP substrate is then 
added.  The alkaline phosphatase in the antibody conjugate reacts with 
the pNPP to form para-nitrophenoxide and phosphate.  Increasing 
absorbance due to formation of para-nitrophenoxide is monitored at 405 
nm and 450 nm.   
o The colour production in the reaction is inversely proportional to the 
progesterone concentration.   
The inter and intra assay coefficients of variation are less than 10%. 
Our test series of 4 samples comparing the two methods confirms a 2-3 nmol 
between-method variation, as quoted by UK National External Quality 
Assessment Service (NEQAS). This is taken into account during statistical 
analysis. 
 
3.4.3 17 - α-OH progesterone assay 
This was quantified using an enzyme linked immunoassay DSL-10-6800 
ACTIVE (Diagnostic Systems Laboratories, USA) and expressed as ng/mL.  
This ELISA uses the competitive binding enzyme immunoassay format.  In the 
assay, standards, controls and unknowns containing 17α-OH progesterone (17-
OHP) are incubated with biotin-labeled 17-OHP and rabbit anti-17-OHP 
antiserum in microtitration wells coated with goat anti-rabbit gamma globulin 
where the unlabeled and biotin-labeled antigens compete for a limited number 
of anti-17α-OH progesterone binding sites.  After incubation and washing, the 
wells are incubated with streptavidin-horseradish peroxidase (HRPO), which 
binds to the biotinylated 17α-OH progesterone.  The unbound streptavidin- 
HRPO is washed away, followed by incubation with the substrate 
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tetramethylbenzidine (TMB).  An acidic stopping solution is then added to stop 
the competition reaction, and the degree of enzymatic turnover of the substrate 
is determined by dual wavelength absorbance measurement at 450 and 620 
nm.  The intra-assay coefficients of variation were 5.1% at 0.49 ng/mL and 
4.9% at 6.13 ng/mL, the inter-assay coefficients of variation were 6.76% at 0.49 
ng/mL and 5.38% at 6.63 ng/mL.   
Assay Procedure 
1.  Pipet 50 µL of the standards, controls and unknowns into the microtiter 
wells.   
2.  Add 50 µL of the 17-OHP biotin conjugate solution to each well. 
3.  Add 100 µL 17-OHP antiserum to each well. 
4.  Incubate the wells shaking at a fast speed (500-700 rpm) at room 
temperature (~25°C) for 1 hour.   
5.  Aspirate and wash each well 5 times with the wash solution and 
blot dry. 
6.  Add 200 µL of streptavidin-enzyme conjugate solution to each well. 
7.  Incubate the wells shaking at a fast speed (500-700 rpm) on an orbital 
microplate shaker, for 30 minutes at room temperature (~25°C).   
8.  Aspirate and wash each well 5 times with the wash solution and blot dry.   
9.  Add 100 µL of the TMB chromogen solution to each well. 
10.  Incubate the wells shaking at a fast speed (500-700 rpm) at room 
temperature (~25°C) for 30 minutes.   Avoid exposure to direct sunlight.   
11.  Add 100 µL of the stopping solution to each well.   
12.  Read the absorbance of the solution in the wells within 30 minutes, using a 
microplate reader set to 450 nm.    
 
 53 
3.4.4 Inhibin A assay 
Inhibin A was quantified using an enzymatically amplified "two-step" sandwich-
type immunoassay DSL-10-28100 ACTIVE (Diagnostic Systems Laboratory, 
USA) and expressed as pg/mL.  In the assay, duplicates of standards, controls 
and unknown serum samples are incubated in microtitration wells that have 
been coated with anti-inhibin βA subunit antibody.  After incubation and 
washing, the wells are treated with another anti-inhibin alpha subunit detection 
antibody labelled with the enzyme horseradish peroxidase (HRP).  After a 
second incubation and washing step, the wells are incubated with the substrate 
tetramethylbenzidine (TMB).  An acidic stopping solution is then added and the 
degree of enzymatic turnover of the substrate is determined by dual wavelength 
absorbance measurement at 450 and 620 nm.  The absorbance measured is 
directly proportional to the concentration of inhibin A present.  A set of inhibin A 
standards were used to plot a standard curve of absorbance versus inhibin A 
concentration from which the inhibin A concentrations in the unknowns can be 
calculated.   
Assay Procedure 
1.  Pipet 50 µL of the standards, controls, and unknowns to the wells of the 
microtitre plate.   
2.  Add 50 µL of Inhibin A sample buffer A to each well. 
3.  Add 50 µL of Inhibin A sample buffer B to each well. 
4.  Incubate the wells, shaking at 500-700 rpm on an orbital microplate shaker, 
for 3 hours at room temperature.   
5.  Aspirate and wash each well 6 times with the Wash Solution and blot dry.   
6.  Add 100 µL of the Inhibin A antibody-enzyme conjugate solution to each 
well.   
7.  Incubate the wells on an orbital microplate shaker set at 500-700 rpm for 1 
hour at room temperature.   
8.  Aspirate and wash each well 6 times with the wash solution and blot dry 
9.  Add 100 µL of the TMB chromogen solution to each well  
10.  Incubate the wells on an orbital microplate shaker set at 500-700 rpm for 15 
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minutes at room temperature.  Avoid exposure to direct sunlight.   
11.  Add 100 µL of the stopping solution to each well using a semi-automatic 
dispenser.   
12.  Read the absorbance of the solution in the wells within 30 minutes, using a 
microplate reader set to 450 nm.   
 
3.4.5 Inhibin proαC-RI assay 
Inhibin pro-αC was quantified using a solid phase sandwich ELISA (Oxford Bio-
Innovation MCA 1254KZZ), and expressed as pg/mL.  The wells of a microtitre 
plate come dry-coated with a monoclonal antibody specific for the pro region of 
the alpha subunit of inhibin.  Samples are incubated in the wells so that the 
antigen binds to the ‘capture’ or immobilised antibody via its pro region of the 
alpha subunit.  Following washing of the plate a ‘second’ or detection antibody 
is added.  This is the Fab fragment of a monoclonal antibody specific to the 
alpha subunit of inhibin coupled to alkaline phosphatase.  Any unreacted 
material is then removed by washing before the detection of alkaline 
phosphatase using a sensitive amplified substrate reaction.  This results in a 
red reaction product with a colour intensity which is directly proportional to the 
concentration of inhibin-pro-αC related materials present in the original sample.  
The assay has less than 0.1% cross reactivity with inhibin A, inhibin B, activin A, 
activin B and follistatin.   
Assay Procedure 
1.  Add 50 µL of each sample and standard dilution in duplicate, to the wells of 
the microtitre plate. 
2.  Add 50 µL of assay diluent in duplicate wells as a zero analyte sample.  
Cover the plate with a plate sealer and incubate overnight at 4oC. 
3.  To 1 vial of MCA1254A alkaline phosphatase conjugated Fab mouse anti 
human inhibin alpha subunit, add 1 mL of pro-αC assay diluent.  Replace 
the top and mix.   Remove the contents and add to a further 5 mL of assay 
diluent. 
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4.  Wash the wells of the microtitre plate by filling each well to the top with Pro-
αC washing buffer allowing to stand for about 15 seconds and then 
decanting or aspirating each well thoroughly.   Repeat this step a further 3 
times.  Invert the plate to drain on absorbent paper. 
5.  Add 50 µL MCA1254A prepared in step 3 to each well of the microtitre plate. 
6.  Cover and seal the plate and incubate at room temperature for 1 hour. 
7.  Wash as in step 4 but with 8 cycles and ending with the wells filled with 
buffer.   Leave the plate to soak for 15 minutes at room temperature whilst 
preparing the substrate. 
8.  Prepare the substrate by adding the substrate diluent to the lyophilised 
substrate.  Mix for 5 minutes.   
9.  Remove the buffer from the plate wells and further wash the plate for 2-3 
cycles.   Drain the plate dry by inversion on absorbent paper. 
10.  To each well of the plate add 50 µL of substrate solution. 
11.  Cover and seal the plate and incubate at room temperature for 2 hours. 
12.  Prepare the amplifier by adding the amplifier diluent to the lyophilised 
amplifier.   Mix for 5 minutes. 
13.  To each well of the plate add 50 µL of amplifier solution.  Agitate gently to 
mix. 
14.  Cover the plate and incubate at room temperature.  Colour will appear quite 
rapidly.  Read the absorbance values, at 5 minute intervals, of each well at 
490 nm.  Preferably referencing at 620 nm. 
15.  Stop the reaction by the addition of 50 µL of STOP solution to each well 
when the 200 pg/mL standard has reached an absorbance of 2.0 at 490 nm 
(approximately 10-20 minutes depending on ambient temperature). 
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3.4.6 IGFBP-1 assay 
IGFBP-1 levels were quantified using The ACTIVE Total IGFBP-1 ELISA 
(Diagnostic Systems Laboratories, USA), an enzymatically amplified two-step 
“sandwich” assay, and expressed as µg/L.  In the assay, standards, controls 
and samples are incubated in microtitration wells which have been coated with 
anti-IGFBP-1 antibody.  After incubation and washing, anti-IGFBP-1 detection 
antibody labeled with enzyme- horseradish peroxidase (HRP) is added to each 
well.  After a second incubation and washing step, the substrate 
tetramethylbenzidine (TMB) is added to the wells.  The reaction is then 
terminated by adding an acidic stopping solution.  The degree of enzymatic 
turnover of the substrate is determined by dual wavelength absorbance 
measurement at 450 nm and between 600 and 630 nm.  The absorbance 
measured is directly proportional to the concentration of IGFBP-1 in the 
samples.  A set of IGFBP-1 standards were used to plot a standard curve of 
absorbance versus IGFBP-1 concentration.  The total IGFBP-1 concentrations 
in the samples were then calculated from this standard curve.  The inter- and 
intra-assay coefficients of variation are less than 10%. 
Assay Procedure 
1.  Pipette 25 µL of the standards, controls and samples assay into the 
appropriate microtiter wells. 
2.  Add 50 µL of the assay buffer to each well. 
3.  Incubate the wells, shaking at 500-700 rpm on an orbital microplate shaker, 
for one hour at room temperature. 
4.  Aspirate and wash the wells 5 times with the wash solution and blot dry. 
5.  Pipette 100 µL of the antibody-enzyme conjugate into the wells. 
6.  Incubate the wells, shaking at 500-700 rpm on an orbital microplate shaker 
for 30 minutes at room temperature. 
7.  Wash the wells 5 times with the wash solution and blot dry. 
8.  Add 100µL of TMB chromogen solution into each well. 
9.  Incubate the wells, shaking at 500-700 rpm on an orbital microplate shaker 
for 10 minutes at room temperature. 
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10.  Stop the reaction by adding 100 µL of stopping solution into each well. 
11.  Measure the absorbance of the solution in the wells within 30 minutes, 
using a microplate reader set to 450 nm. 
 
3.4.7 H-hCG assay 
A specific monoclonal antibody to hCG-H (antibody B152) was generated 
against the hCG with 100% hexasaccharide O-linked structures (100% H-hCG) 
produced by a single patient with choriocarcinoma by Cole et al.,  (1999).  Using 
this monoclonal antibody a microtiter plate two antibody (B152 plus anti-β 
tracer) assay was established for detecting intact H-hCG.  H-hCG was 
quantified using this two-step sandwich-type ELISA, and expressed as µg/L.  
The inter-assay variance is 8.9%.  The microtiter plate assay recognizes H-hCG 
(100% immunoreactivity), sialic acid deficient H-hCG (100%), H-hCG free β-
subunit (60%), pure CHO-cell recombinant hCG (<1%), and pure CHO 
(Chinese Hamster ovary) -cell recombinant hCG free β-subunit (<1%) (Cole et 
al., 1999). 
Assay procedure 
1.  Microtiter plates are coated by incubation 16-24 hours at 4oC with capture 
antibody (0.2 mL per well of a solution containing 2.5 mg/L antibody B152 in 
0.25 mol/L NaHCO3  and 0.1 mol/L NaCl).   
2.  Plates are washed three times with water and blotted dry 
3.  Wells are blocked with phosphate-buffered saline, pH 7.4, containing 10 g/L 
bovine serum albumin and 0.4 g/L sodium azide.   
4.  Incubate for 1 hour at room temperature, then plates are again washed three 
times with water and blotted dry. 
5.  C5 hCG at concentrations of 0, 60, 12 and 2.4 µg/L is added to 
quadruplicate wells of the plate.  Buffer is added, and the plates are incubated 
for 4 hours at room temperature on an orbital plate shaker.   
6.  Plates are again washed 3 times with water and blotted dry.   
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7.  Tracer antibody is added to each well.  After an additional 2 hours incubation 
at room temperature on the plate shaker, plates are again washed three times 
with water and blotted dry.   
8.  0.2 mL of substrate is added to each well.   
9.  Incubate for 15 minutes at room temperature 
10.  The reaction is stopped by the addition of 0.05 mL of HCl.   
11.  The plates are read on a microtiter plate reader at 450 nm.   
 
3.4.8 Chromatography methods 
Partially purified hCG was prepared from 1 mL maternal serum by ion-exchange 
chromatography.  Fractions containing hCG were pooled and chromatographed 
on Superdex 75 pg 16/60 or immobilised lectins, equilibrated in 20 mmol/L Tris 
HCl, 500 mmol/L NaCl; pH 7.4.  For lectin chromatography, samples were either 
run on individual columns of concanavalin-A (Con-A), Lens culinaris agglutinin 
(LCA), and wheat germ agglutinin (WGA), or Con-A and WGA columns in 
series. 
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A.  Ion-exchange chromatography 
o Ion exchange columns, 5 mL Sepharose-Q, are generated by washing in 
20mmol/L Tris, pH 7.4, 1 M/L NaCl, followed by 20 mmol/L Tris pH 7.4 
o Maternal serum, 1 mL, is desalted on 5 mL Sephadex (Hi-Trap – 
desalting) column in 20 mmol/L Tris, pH 7.4 
o Desalted serum sample is applied to ion-exchange column 
o Protein is eluted from ion-exchange column in a 0 – 1 M/L NaCl gradient 
o Fractions containing hCG immunoactivity are pooled and retained for 
either gel-filtration or lectin affinity chromatography. 
 
B.  Gel filtration chromatography 
o Gel chromatography columns, Sephadex 75 pg 16/60, are equilibrated in 
20 mmol/L Tris pH 7.4, 0.5 M NaCl/L and calibrated with dextran blue, 
albumin, 63.7 kDa, ovalbumin, 48.6 kDa, chymotrypsinogen A, 20 kDa 
and ribonuclease A, 15.7 kDa (low molecular weight gel filtration 
calibration kit; Amersham Pharmacia Biotech). 
o Protein is eluted with 20 mmol/L Tris pH 7.4, 0.5 M NaCl/L at 1 mL/min. 
o Fractions are assayed for hCG immunoactivity. 
 
C.  Lectin affinity chromatography 
o Columns of 1 mL.  immobilised lectin (ConA, WGA, LCA – Sepharose) 
are generated by washing in 20 mL 20 mmol/L Tris, pH 8.5, 1 M/L NaCl 
followed by 20 mL 20 mmol/L Tris, pH 7.4, 0.5 M NaCl/L, 1 mmol/ CaCl2, 
MnCl2, MgCl2. 
o Immunoactive hCG is run on to the column, washed with 20 mmol/L Tris, 
pH 7.4, 0.5 M NaCl  
o  Bound immunoactive hCG is eluted from lectin by appropriate sugar.   
o Fractions are assayed for hCG immunoactivity. 
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Gel filtration chromatography 
Partially purified samples as described above were chromatographed on 
superdex pg 75.  Partition coefficients (Kav) were derived from calibration using 
dextran blue, albumin, 63.7 kDa, ovalbumin, 48.6 kDa, chymotrypsinogen A, 20 
kDa and ribonuclease A, 15.7 kDa (low molecular weight gel filtration calibration 
kit; Amersham Pharmacia Biotech). 
 
Lectin affinity chromatography 
(i) Lectin columns were washed at 1 mL/min and unbound protein collected in 1 
ml fractions for 20 column volumes.  Bound protein was eluted from lectin 
columns in either 500 mmol/L mannose (Con-A and LCA) or 500 mmol/L N-
acetyl-glucosamine (GlcNAc) (WGA), in 20 mmol/L Tris HCl, 500mmol/L NaCl 
pH 7.4, at 1 mL/min over 10 column volumes.  1 mL fractions were collected.  
Fractions containing bound and unbound protein were assayed for hCG 
immunoactivity. 
 
(ii) Pooled fractions containing hCG immunoactivity from ion-exchange 
chromatography were applied to Con A columns as above and washed with 20 
column volumes of Tris HCl, 500 mmol/L NaCl pH 7.4.  The eluent containing 
unbound protein was discarded.  A column containing WGA, 1 mL, was then 
connected in series after the Con A column.  Protein which had bound to the 
Con A column was eluted with 500 mmol/L mannose, the eluent passing 
through the WGA column, to a total of 15 column volumes.  Protein which 
bound to WGA after being displaced from Con A by 500 mmol/L mannose, was 
finally eluted from the WGA column by 40 column bed volumes 500 mmol/L 
GlcNAc. 
 
Resolution of hCG isoforms 
Binding of serum hCG to WGA was further assessed on unfractionated serum 
samples.  Serum, 50 mcL, was made up to 2.5 mL final volume in Tris HCl, 500 
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mmol/L NaCl, pH 7.4 and applied directly to 1 mL.  WGA equilibrated in the 
same buffer at 0.2 mL/min the initial ion-exchange step having been omitted.  
After washing with 10 column volumes, a gradient of 3-15 mmol/L GlcNAc was 
run through the column and 50 fractions (volume 2 mL) were collected at 0.2 
mL/min.  Fractions were assayed for hCG content (Immulite 2000). 
 
3.5 STATISTICAL ANALYSIS 
All data collected were stored in Microsoft Excel spreadsheets.  The Statistical 
Package for Social Sciences, version 16.0 (SPSS, Statistical Analysis Systems, 
Chicago, Illinois, USA) was used for all calculations. 
3.5.1 Decision tree analysis 
The Classification and Regression Trees (C&RT) tree-building algorithm, within 
SPSS version 16.0, was used to ‘grow’ the trees.  This is a recursive partitioning 
method for predicting continuous dependent variables (regression) and 
categorical predictor variables (classification) (StatSoft, 2011).  It determines a 
set of if-then logical (split) conditions through sequential analysis of variables.  
The algorithm finds the split at each node that will generate the greatest 
improvement in predictive accuracy and so permits accurate prediction or 
classification of cases.  The resulting ‘trees’ have the advantages of mimicking 
clinical decision-making and, as no presumptions are made about relationships 
between variables, they are particularly useful when there is no a priori 
knowledge. 
The stopping rules for the iterative process were set as the following; the tree 
should have a maximum of five levels, a minimum of five cases were to be 
present for a split to be calculated, and any given split should not generate a 
group with less than two cases.  Limiting the number of levels to five avoids 
‘overfitting’, which is particularly important with a small data set.  V-fold cross-
validation repeats the analysis many times over with different randomly drawn 
samples from the data.  This was used to validate our decision-trees and is a 
powerful and essential step for generating useful trees. 
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Decision trees attempt to find a strong relationship between input values and 
target values in a group of observations that form a data set.  When a set of 
input values is identified as having a strong relationship to a target value all of 
these values are grouped, and that becomes a branch on the decision tree.  
Decision trees are a simple but powerful form of multiple variable analysis and 
the resulting trees present the data and relationships in a form that is readily 
understandable and applicable.  They can be used as the basis for ‘clinical 
decision rules’ that help to translate findings from original research studies into 
clinical practice (Ebell, 2010). 
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CHAPTER 4.  GLYCOSYLATION OF MATERNAL SERUM HCG IN 
EARLY PREGNANCY 
4.1 INTRODUCTION 
Human chorionic gonadotrophin (hCG) is a glycoprotein hormone produced by 
trophoblast that was first identified in 1927 (Ascheim & Zondek, 1927).  hCG is 
a heterodimer composed of α- and β- subunits which are non-covalently bound.  
The α-subunit is shared with the other glycoprotein hormones, luteinizing 
hormone, follicular stimulating hormone, and thyroid stimulating hormone, 
whereas the β- subunit is specific for each hormone.  By the 1970s the amino 
acid sequences of the hCG subunits had been determined and it was found that 
hCG contained 4 N-linked and 4 O-linked oligosaccharides of variable structure 
(Bahl 1969b; Bahl et al., 1972; Morgan et al., 1975; Kennedy & Chaplin, 1976; 
Kessler et al., 1979; Green et al., 1986).  These carbohydrates make up about 
one-third of the molecular weight of hCG and the glycosylation is of structural 
and functional importance, affecting the signal transduction and the half-life of 
the hormone (Lustbader et al., 1998).   
HCG, like the other glycoprotein hormones, exists as a family of ‘glycoforms’ 
which differ in their oligosaccharide structures (Lambert et al., 1998).  The 
hormone hCG has a high degree of structural heterogeneity associated with 
these differences in carbohydrate moieties, in particular the terminal sialic acid 
residues.  These are the major determinant of the charge of the hCG glyco-
isoforms (Abushoufa et al., 2000).  These glyco-isoforms of hCG have been 
demonstrated within normal pregnancy, failing pregnancy and trisomy 21 
pregnancy (Elliott et al., 1997; O’Connor et al., 1998; Abushoufa et al., 2000). 
One of the roles of hCG is the promotion of progesterone synthesis through 
early pregnancy.  In early pregnancy hCG promotes progesterone production by 
the corpus luteal cells, this is essential to maintaining pregnancy (Csapo et al., 
1973).  The corpus luteum replaces pituitary LH in controlling progesterone 
production from implantation to around 7-9 weeks of gestation, from when the 
syncytiotrophoblast cells make progesterone independent of hCG stimulation 
until term.  This is known as the luteal-placental shift (Csapo et al., 1973).  The 
need for production of hCG throughout pregnancy has recently been explained 
 64 
as hCG has been found to have critical functions in trophoblast differentiation 
and in fetal nutrition through myometrial spiral artery angiogenesis (Cole, 2009).  
Recently, using antibodies against specific epitopes within hCG molecules 
derived from choriocarcinoma hCG, a hyperglycosylated variant of hCG, known 
as hyperglycosylated hCG (H-hCG), has been identified.  H-hCG is made by 
extravillous cytotrophoblast cells (Kovalevskaya, 2002a) whereas villous 
syncytiotrophoblast cells make ‘regular’ hCG.  H-hCG also differs from regular 
hCG in structure and function (Skarulis et al., 1992; Kovalevskaya et al., 1999; 
Cole et al., 1997).  Regular hCG and H-hCG have the same peptide sequence 
with structural differences only in their oligosaccharide side chains (Elliott et al., 
1997).  H-hCG glycosylation differs from regular hCG with a tendency to greater 
branching of the N-linked oligosaccharides and much larger O-linked 
oligosaccharides (Elliott et al., 1997; Kobata & Takeuchi, 1999; Valmu et al., 
2006).   
H-hCG is the predominant form of hCG produced in the first week of pregnancy 
and this variant is an autocrine (rather than endocrine) factor.  H-hCG inhibits 
apoptosis in extravillous invasive cytotrophoblast cells promoting cell invasion 
and growth (Cole, 2009) thus it is critical to efficient placentation and therefore 
for successful pregnancy.  At three weeks gestation H-hCG comprises 89% of 
total hCG immunoactivity, falling to 16% by seven weeks gestation, 5% at 9 
weeks and < 1.3% after 14 weeks (Cole, 2009).  Total hCG, therefore, 
undergoes a shift in glycosylation, from predominantly H-hCG forms to regular 
hCG.  
We have hypothesised that the shift from H-hCG to regular hCG is associated 
with further modifications to hCG glycosylation and that this pattern of 
glycosylation is important for successful pregnancy.  In order to test this 
hypothesis we have identified glyco-isoforms of total hCG, based upon lectin 
binding, through late first trimester and into the second trimester.  We have 
compared our findings from successful pregnancies to those seen in failing 
pregnancies.  Samples were also assayed for hCG and H-hCG to investigate 
the contribution of these to any differences seen.  
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4.2 STUDY DESIGN 
This was a prospective study of 76 women who presented to the early 
pregnancy assessment unit or the antenatal clinic at Sunderland Royal Hospital.  
All women underwent an ultrasound scan to determine the viability and 
gestation of their pregnancy.  Gestation was calculated from the date of the last 
menstrual period and subsequently altered according to scan findings when a 
discrepancy of seven or more days existed (as per departmental guidelines).  
Venous blood samples were taken from all of the women.  Samples were 
allowed to clot at room temperature, centrifuged and serum stored in 1 mL 
aliquots at -30°C until analysis.  Written, informed consent was given by all 
participants.  Final pregnancy outcomes were identified from the hospital patient 
database and dichotomised into failed (including both failures at initial scan and 
subsequent failures) and viable pregnancies.  Viability at anomaly scan was 
used as a surrogate measure of viability when delivery had not yet taken place 
at time of data collection.  
The study was approved by Sunderland Local Research Ethics Committee.   
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4.3 METHODS 
4.3.1  Gross structure and general characteristics of maternal serum hCG 
Partially purified hCG was prepared from 1 mL maternal serum by ion-exchange 
chromatography.  Fractions containing hCG were pooled and chromatographed 
on Superdex 75 pg 16/60 or immobilised lectins, equilibrated in 20 mmol/L Tris 
HCl, 500 mmol/L NaCl; pH 7.4.    
For lectin chromatography, samples were either run on individual columns of 
Concanavalin-A Sepharose (Con-A), Lens culinaris agglutinin Sepharose 
(LCA), and wheat germ agglutinin Sepharose (WGA), or Con-A and WGA 
columns in series.  
a.  Gel filtration chromatography 
Partially purified samples as described above were chromatographed on 
superdex pg 75.  Kav were derived from calibration using dextran blue, albumin, 
63.7 kDa, ovalbumin, 48.6 kDa, chymotrypsinogen A, 20 kDa and ribonuclease 
A, 15.7 kDa (low molecular weight gel filtration calibration kit; Amersham 
Pharmacia Biotech).  
b.  Lectin affinity chromatography 
(i) Lectin columns were washed at 1 mL/min and unbound protein collected in 1 
mL fractions for 20 column volumes.  Bound protein was eluted from lectin 
columns in either 500 mmol/L mannose (Con-A and LCA) or 500mmol/L 
GlcNAc (WGA), in 20 mmol/L Tris HCl, 500 mmol/L NaCl pH 7.4, at 1 mL/min 
over 10 column volumes.  1 mL fractions were collected.  Fractions containing 
bound and unbound protein were assayed for hCG immunoactivity.  
(ii) Pooled fractions containing hCG immunoactivity from ion-exchange 
chromatography were applied to Con A columns as above and washed with 20 
column volumes of Tris HCl, 500 mmol/L NaCl pH 7.4.  The eluent containing 
unbound protein was discarded.  A column containing WGA, 1 mL, was then 
connected in series after the Con A column.  Protein which had bound to the 
Con A column was eluted with 500 mmol/L mannose, the eluent passing 
through the WGA column, to a total of 15 column volumes.  Protein which 
bound to WGA after being displaced from Con A by 500 mmol/L mannose, was 
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finally eluted from the WGA column by 40 column bed volumes 500 mmol/L 
GlcNAc.  
 
4.3.2  Resolution of hCG isoforms 
Binding of serum hCG to WGA was further assessed on unfractionated serum 
samples.  Serum, 50 mcL, was made up to 2.5 mL final volume in Tris HCl, 500 
mmol/L NaCl, pH 7.4 and applied directly to 1 mL.  WGA equilibrated in the 
same buffer at 0.2 mL/min the initial ion-exchange step having been omitted.  
After washing with 10 column volumes, a gradient of 3-15 mmol/L GlcNAc was 
run through the column and 50 fractions (volume 2 mL) were collected at 0. 2 
mL/min.  Fractions were assayed for hCG content.  A selection of samples from 
the peaks of concentration were assayed for H-hCG.  
 
4.3.3 hCG assay 
Measurement of hCG was by commercially available immunoradiometric assay 
(Vankrieken & De Heotogh, 1995) on Immulite 2000 (Diagnostic Products 
Corporation, Los Angeles, CA, USA) which is highly sensitive for both hCG and 
H-hCG (Cole et al., 2004).  
 
4.3.4 H-hCG assay 
Peaks of hCG immunoactivity from WGA chromatography were concentrated by 
ultracentrifugation (Amicon Ultra-4 Centrifuge Filter Units; Millipore UK Ltd, 
Hertfordshire, UK), reconstituted and assayed for H-hCG using monoclonal 
antibody B152 microtiter plate assay which recognizes H-hCG with 100% 
immunoreactivity (Cole et al., 1999).  
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4.3.5 Statistical analysis 
For statistical, graphic and tabulated presentation, chromatography results, 
measured as hCG U/L /fraction, were expressed as the percentage within each 
fraction of the total hCG eluted from the column.  Mann-Whitney U-test was 
used to compare the heights of the peak values of discrete hCG isoforms.  
Results were tabulated as the median value and ranges of the peak values for 
each isoform.  
 
4.4 RESULTS 
4.4.1  Gross structure and general characteristics of maternal serum hCG 
The stability of hCG and specificity of hCG affinity for WGA were demonstrated 
by gel filtration chromatography and lectin affinity chromatography on ConA / 
WGA in series respectively.  Gel filtration chromatography, following ion-
exchange chromatography, of 1 mL serum (20-fold greater starting volume than 
that used for WGA chromatography) revealed a single peak of hCG 
immunoactivity, Kav= 0.34- 0.36, with no difference between any groups.  No 
hCG immunoactivity was identified eluting with a smaller molecular size which 
could be considered indicative of free β-hCG.  Using a starting volume of 1 ml 
serum, hCG was eluted from WGA in 500 mmol/L GlcNAC but not 500 mmol/L 
mannose, indicative of specific WGA-hCG binding and elution.  
Of the three lectins tested, 100% hCG binding to ConA and WGA was 
observed, whereas hCG binding to LCA varied between 23-27%.  No significant 
difference in binding between samples from various lengths of gestation or 
pregnancy outcome was found.  When samples were chromatographed on 
columns of ConA and WGA in series, hCG from all sources bound to WGA, 
from which it was eluted specifically by 500 mmol/L GlcNAc but not 500 mmol/L 
mannose.   
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4.4.2 Resolution of hCG isoforms 
Chromatography on WGA of serum hCG identified 5 distinct hCG glyco-
isoforms when eluted by a 3–15 mmol/L GlcNAc gradient.  Each of these glyco-
isoforms was present at all stages of gestation (see Figure 14).  When samples 
from early, <8 weeks gestation, were compared to those from second trimester, 
16–20 weeks gestation, highly significant differences in the relative expression 
of each isoform were observed (see Figure 14 and Table 7).   
 
 
 
Median values for:  
   <8 weeks 
                              8-<12 weeks 
                            12-<16 weeks 
                            16-<20 weeks 
 
Samples, 50mcL maternal serum, eluted in 3-15 mmol/L GlcNAc gradient through 1 mL 
immobilised lectin over 80 mL.   
Fraction volume = 2 mL.  
Results expressed as percentage / fraction of total hCG immunoactivity eluted from 
column (y axis) against fraction (x axis).  
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Figure 14. WGA lectin affinity chromatography by gestational age 
 
 Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 
<8weeks gestation      
Median peak value, n=17 1.07 2.58 4.92 6.70 3.97 
Range 0.48-3.06 0.59-6.41 2.11-19.25 2.73-14.14 
0.62-
14.77 
>16-20 weeks gestation      
Median peak value, n=20 2.43 5.06 6.76 4.48 0.73 
Range 1.16-10.83 3.16–11.64 4.05-11.13 1.59-13.62 
0.36-
2.77 
      
Mann-Whitney U-test P<0.001*  P=0.0001* P=0.0142* P=0.003* P<0.001* 
      
* significant at P < 0.05 
Table 7. Comparison of median peak values between samples at <8 weeks 
(n=17) and >16-20 weeks gestation (n=20) 
 
Comparison of samples from <8, 8-<12, 12-<16 and 16-20 weeks gestation 
showed that the major shift in hCG glycoform expression occurred between <8 
and 8-<12 weeks gestation.  Thereafter little difference in hCG glyco-isoform 
expression occurred (see Figure 14 and Table 8).  
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 Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 
<8 weeks gestation       
Median peak value, 
n=17 1.07 2.58 4.92 6.70 3.97 
Range 0.48-3.06 0.59-6.41 2.11-19.25 2.73-14.14 0.62-14.77 
8-<12 weeks 
gestation      
Median peak value, 
n=13 2.43 5.98 5.53 5.43 2.05 
Range 0.78-5.01 1.96-11.50 1.51-10.80 3.14-10.88 0.83-11.20 
      
Mann – Whitney U-
test  P=0.0009* P=0.0013*  P=0.55 P=0.1026 P=0.0107* 
8-<12 weeks 
gestation      
Median peak value, 
n=13 2.43 5.98 5.53 5.43 2.05 
Range 0.78-5.01 1.93-11.50 1.51-10.80 3.14-10.88 0.83-11.20 
12-<16 weeks 
gestation      
Median peak value, 
n=8 2.12 5.40 6.28 5.43 1.93 
Range 1.60-3.85 4.39-8.22 4.93-8.18 3.55 – 6.93 1.00–3.55 
      
Mann-Whitney U-test P=0.5382 P=0.9135 P=0.685 P=0.7999 P=0.7445 
12-<16 weeks 
gestation      
Median peak value, 
n=8 2.12 5.40 6.28 5.43 1.93 
Range 1.60 - 3.85 4.39 - 8.22 4.93 - 8.18 3.55 – 6.93 1.00 – 3.55 
>16-20 weeks 
gestation      
Median peak value, 
n=20 2.43 5.06 6.76 4.48 0.73 
Range 1.16–10.83 3.16-11.64 4.05-11.13 1.59-13.62 0.36–2.77 
      
Mann-Whitney U-test P=0. 0236* P=0. 939 P=0. 6655 P=0. 2742 P=0. 0018* 
* significant at P < 0. 05 
 
Table 8.  Comparison of median peak values between successive stages 
of early pregnancy.  
 
Significant differences are apparent between samples between <8 (n=17) and 
8-<12 (n=13) weeks pregnancy.  No difference is a observed between 8-<12 
(n=13) and 12-<16 (n=8) weeks gestation.  Some difference between 12-<16 
(n=8) and >16-20 (n=20) weeks gestation.  The greatest difference between 
successive stages is observed for that between <8 and 8-<12 weeks gestation.  
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Chromatography on WGA of samples from failing pregnancies at <8 weeks 
gestation showed significantly different hCG glyco-isoform expression as 
compared with viable pregnancies at similar gestations (see Figure 15 and 
Table 9).  
 
 
Median values for    viable __________   & failed ---------  pregnancies 
 
Samples, 50 mcL maternal serum, eluted in 3-15 mmol/L GlcNAc gradient through 1 mL 
immoblised lectin over 80 mL.   
Fraction volume = 2 mL.  
Results expressed as percentage / fraction of total hCG immunoactivity eluted from column (y 
axis) against fraction (x axis).  
 
Figure 15.  WGA lectin affinity chromatography by pregnancy outcome
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 Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 
<8weeks 
gestation; viable      
Median peak 
value, n=17 1.07 2.58 4.92 6.70 3.97 
Range 0.48-3.06 0.59-6.41 
2.11-
19.25 2.73-14.14 0.62-14.77 
<8weeks 
gestation; failed      
Median peak 
value, n=18 2.32 5.31 4.85 4.71 2.71 
Range 1.12-5.98 
1.091-
11.64 
1.93-
10.79 1.33-15.86 0.30-5.79 
      
Mann Whitney U 
test P=0.0003* P=0.0079* P=0.986 P=0.0259* P=0.0333* 
      
*significant at P < 0. 05 
 
Table 9.  Comparison of median peak values observed for samples at less 
than 8 weeks gestation between viable (n=17) and failed (n=18) 
pregnancies.   
 
4.4.3 Hyperglycosylated hCG 
60 samples from fractions at the peaks of hCG immunoactivity were assayed for 
H-hCG, 30 from pregnancies which were successful and 30 from pregnancies 
which failed.  In all but 5 of these samples H-hCG was undetectable (<20 
ng/mL).  
 
4.5 DISCUSSION 
In this study, five major glyco-isoforms of hCG have been identified in early 
pregnancy on the basis of their differing affinities for WGA.  These isoforms are 
expressed throughout early gestations and display a well-ordered progression 
through early pregnancy and a marked and rapid shift at around eight weeks of 
gestation.  The concentration of maternal serum hCG is known to vary with 
gestation and pregnancy viability.  We have taken this into account by 
expressing results for each chromatography run as a percentage within each 
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fraction of the total hCG recovered from the column.  Analysis of our data is not, 
therefore, affected by variations in initial serum hCG concentration.  
hCG is detectable during pregnancy in maternal urine and serum following 
implantation (Skarulis et al., 1992).  It consists of two dissimilar subunits, α and 
β, which are glycosylated and non-covalently bound (Pierce & Parsons, 1981).  
Glycosylation is considered to play an important role in the bio-availability and 
bio-activity of glycoprotein hormones in general (Willey, 1999) and hCG in 
particular (Channing et al., 1978; Moyle et al., 1975; Merz, 1988; Birken et al., 
1996).  Post-translational glycosylation comprises the addition of two N-linked 
oligosaccharides to each subunit; on amino acids 52 and 78 (α subunit) and 13 
and 30 (β subunit).  In addition to N-linked oligosaccharides, 4 O-linked 
oligosaccharides are located within the hCG-β–COOH terminus (Bahl, 1969b).   
As previously described H-hCG is the predominant glyco-isoform detected in 
early pregnancy.  This early H-hCG form declines rapidly to be replaced by 
hCG, which then becomes the predominant form (Cole, 2007).  Replacement of 
H-hCG by hCG is a continuous process.  Both hCG and H-hCG have potential 
for multiple structural variations not only between but within their 
oligosaccharide moieties (Kovalevskaya et al., 1999; Sasaki et al., 2008).  By 
the time of the luteal-placental shift the contribution of H-hCG to total hCG 
immunoactivity is minimal, so the variable glycosylation of total hCG at this 
gestation cannot be accounted for on the basis of H-hCG alone.   
Glyco-isoforms of hCG have been demonstrated in normal pregnancy, failing 
pregnancy and trisomy 21 pregnancy by a variety of methods (Skarulis et al., 
1992; Cole et al., 1997; Kovalevskaya et al., 2002b; Diaz-Cueto et al., 1996; 
Nemansky et al., 1998).  The structural basis for this heterogeneity has usually 
been attributed to variation in glycosylation though the precise basis for these 
differences has varied according to techniques employed and gestational age.  
Analysis of serum hCG charge isoforms has indicated changes between 10-11 
and 35-38 weeks gestation (Diaz-Cueto et al., 1996).  Urine and serum hCG, 
together with the free α-subunit, increase in core fucosylation and branching of 
complex oligosaccharides as pregnancy progresses from 7-12 weeks through to 
28-32 weeks gestation (Skarulis et al., 1992; Nemansky et al., 1998).  These 
studies report differences in hCG glycoslyation between temporarily distinct 
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stages of gestation.  We have concentrated on short, consecutive stages of 
early pregnancy in order to investigate how isoforms of hCG develop.  Our data 
show significant changes between early first and early second trimesters with a 
marked shift at 8 - <12 weeks gestation.  
The molecular basis for the resolution of these isoforms is a function of their 
variable N-acetylneuraminic acid (NeuNAc) and/or GlcNAc content, as inferred 
from the known oligosaccharide affinities of WGA.  Saccharides which are 
bound specifically by WGA are 2-acetamido-2-deoxy-D-glucose (GlcNAc) and 
its β-1,4-linked oligomers, and N-acetylneuramic acid (NeuNAc) (Bhavanandan 
& Katlic, 1979; Monsigny et al., 1980; Ming-Chuan, 1992).  With reference to 
hCG, GlcNAc residues are located within N- and O-linked oligosaccharides 
(Bahl, 1969b) and there are two NeuNAC residues on the N-linked 
oligosaccharides of the α- and β-subunits (Kessler et al., 1979).   
We have shown an altered spectrum of hCG oligosaccharide structure at 
around 8 weeks gestation in normal early pregnancy which appears to coincide 
with the luteal-placental shift in progesterone production.  This relatively sudden 
change in five isoforms, identified by WGA affinity chromatography, contrasts 
with the gradual change from H-hCG to hCG which is known to occur.  This shift 
to the left in isoform expression is not only observed with advancing gestation, 
but is also seen when comparing pregnancies that fail with pregnancies that are 
viable.  Failed and failing pregnancies seem to make this shift prematurely.  The 
significance of these findings is yet to be established.   
Other studies have demonstrated variable expression of a single glyco-isoform 
in early successful and failed pregnancies.  These studies have used specific 
antibodies to C5 hCG (monoclonal antibody B152) which is a hyperglycosylated 
structure related to choriocarcinoma hCG.  Relatively high levels of this isoform 
have been described in the first 5-6 weeks gestation, with a subsequent decline 
in expression as pregnancy progresses but which persists in failing pregnancy 
(Kovalevskaya et al., 1999; Kovalevskaya et al., 2002b; Yoshimoto et al., 1979; 
Dean et al., 1980; Sutton-Riley et al., 2006).  Hyperglycosylated hCG differs 
from hCG in its cell of origin and putative functions (Cole, 2007).  How the 
expression of H-hCG relates, if at all, to changes in the physiological spectrum 
of hCG isoforms in early, continuing pregnancy or contributes to the aberrant 
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pattern of hCG which we have described in failed pregnancies is not known.  
We have shown that the progressive expression of hCG in the first 16 weeks of 
continuing pregnancies does not represent any significant H-hCG.  Changes in 
H-hCG alone do not account for our findings; differences in relative expression 
of all 5 isoforms are seen through normal and 3 of 5 failing pregnancies.  
Whether over expression of H-hCG in failing pregnancy is an isolated 
phenomenon or is associated with variable expression of other isoforms is not 
known.   
Variable binding of hCG to WGA has also been reported in quantitative rather 
than qualitative work (Abushoufa et al., 2000).  Isoelectric focusing studies have 
also been reported, but this technique is not specific for glycosylation.  Another 
feature of previous studies is the use of urinary hCG, which is known to have 
undergone desialation (Birken et al., 1996).  Less data are available for serum 
hCG glycoforms.   
Our own data indicate a spectrum of WGA-bound glyco-isoforms each of which 
undergoes changes between early first and second trimesters.  The significance 
of this altered spectrum of hCG oligosaccharide structure at around 8 weeks 
gestation in normal early pregnancy is not clear.  It appears to coincide with the 
luteal to placental shift in progesterone production, which occurs at 
approximately the 7th to the 9th week of gestation (Csapo et al., 1973).   
Variation in hCG glycosylation has been shown to affect signal transduction but 
not hormone-receptor binding (Puett et al., 1996) so, although heterogenous 
hCG receptors have been described, it would seem that they are not a pre-
requisite for differences in hCG biological activity.  The variations in hCG 
glycosylation which we have described may result in different biological effect 
whilst acting through the same hCG receptors.  Changing hCG biological 
activity in early pregnancy does not appear to correlate with the expression of 
hyperglycosylated hCG (Cole, 2007).  Our findings cannot be explained on the 
basis of changes in the relative proportions of H-hCG to hCG alone nor on the 
quantity of hCG applied to, or recovered from, WGA columns, and suggests that 
the expression of appropriate hCG isoforms is a pre-requisite for a successful 
outcome not only in very early pregnancy but also throughout the first trimester.  
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We have described a reproducible and clinically applicable method for 
identifying hCG glyco-isoforms in maternal serum.  The method that we have 
developed is rapid and requires minimal sample volume.  The concentration of 
maternal serum hCG which we have shown can be resolved into isoforms (54-
109,274 U/L) encompasses the full range seen in clinical practice.   
 
4.6 CONCLUSION 
Using lectin-affinity chromatography we have demonstrated hCG glyco-isoforms 
in maternal serum and have identified differences with gestational age and also 
by pregnancy outcome.  We have observed a shift to the left in isoform 
expression with advancing gestation, which failed and failing pregnancies seem 
to make prematurely.  We have shown that changes in H-hCG alone do not 
account for these findings.   
This work provides us with further insight into the endocrinology of early 
pregnancy and possible mechanisms of early pregnancy failure and the role of 
hCG structure.  It forms the basis of a means by which we can increase our 
understanding of the role of hCG isoforms in the physiology of pregnancy.   
 
4.7 SUMMARY OF GLYCOSYLATION OF MATERNAL SERUM HCG IN 
EARLY PREGNANCY 
• Variable glycosylation of hCG can be identified by lectin-affinity 
chromatography with WGA.  
• hCG glyco-isoform expression changes with gestational age.  
• hCG glyco-isoform expression differs in viable as compared to non-viable 
pregnancies at similar gestations.  
• The variations in glycosylation identified cannot be accounted for by 
changes in H-hCG alone.  
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CHAPTER 5. PREDICTION OF SPONTANEOUS RESOLUTION 
OF PREGNANCIES OF UNKNOWN LOCATION USING NOVEL 
BIOCHEMICAL MARKERS 
5.1 INTRODUCTION 
The introduction of transabdominal ultrasound to gynaecology significantly 
improved the management of women with suspected ectopic pregnancy.  The 
combination of a positive pregnancy test and the absence of an intra-uterine 
gestational sac on sonographic examination became generally accepted as an 
indication for laparoscopy.  These observations, however, are not specific to 
ectopic pregnancies and can also be seen in intrauterine pregnancies (IUPs) 
that are too early to visualise, and in complete miscarriages (Ankum et al., 
1993).  With the introduction of high-resolution transvaginal probes the 
diagnosis of ectopic pregnancy has become more accurate, with up to 90% 
visualised ultrasonographically (Condous et al., 2005).  However, in 8-31% of 
patients presenting to an EPAU it is still not possible to confirm the pregnancy 
site by TVS at the first visit (Hahlin et al., 1995; Banerjee et al., 1999; Ankum et 
al., 1993).  The situation, when the location of a pregnancy cannot be confirmed 
as an IUP or an extrauterine pregnancy on the basis of a transvaginal scan, is 
currently classified as a ‘pregnancy of unknown location’ (PUL).  This is a 
descriptive term rather than a pathological diagnosis.   
In current practice PULs are managed conservatively (Sagili & Mohamed, 
2008).  Expectant management is advocated to avoid unnecessary surgical 
intervention and reduce the number and frequency of follow-up visits to a 
minimum.  An expectant management approach based on serum hCG and 
progesterone was initially evaluated by Hahlin and co-workers (Hahlin et al., 
1995).  In their study of 80 women, 45 (56%) pregnancies resolved 
spontaneously, 16 (20%) were ectopic, 7 (9%) miscarried and the remaining 12 
(15%) developed into normal pregnancies.  The surgical intervention rate was 
29%, one third of these procedures were performed to treat miscarriage.  
Banerjee et al., (1999), Facey et al., (2006) and Day et al., (2009) have 
subsequently confirmed that an expectant approach based on hCG and 
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progesterone levels, is safe and has a high success rate, with intervention rates 
of 4-9%.   
The majority of PULs are failing pregnancies.  These include both failing ectopic 
pregnancies and failing intrauterine pregnancies, which are never visualised on 
TVS.  In a prospective observational study in 2001, Banerjee et al. found serum 
progesterone alone to be as accurate as more complex diagnostic models for 
the prediction of successful expectant management of PULs, with a positive 
predictive value of 97% using a cut-off level of 20 nmol/L.  For the group with 
progesterone >20 nmol/L further investigations and follow-up visits are required.  
Facey et al. (2006) in their retrospective evaluation of 103 PULs, identified 7 
failed pregnancies in the 28 patients with an initial progesterone level >20 
nmol/L.  Day et al., (2009) have recently reported a 1.3% intervention rate in 
women with PULs with progesterone </= 10 nmol/L, but less than 50% of their 
PULs fell into this category.  
The main difficulty therefore, with expectant management of pregnancies of 
unknown location is the lack of robust selection criteria, which reliably predict 
the likelihood of successful spontaneous resolution of the pregnancy, 
particularly when the initial progesterone is >20 nmol/L. 
hCG and progesterone are the most commonly used biochemical markers of 
the luteal-trophoblastic axis, hCG is released by the trophoblast within 2 weeks 
of fertilization and then maintains the progestagenic activity of the corpus lutem.  
Over the last 10 years several new biochemical markers of the luteal-
trophoblastic axis have been described.  IGFBP-1 is one of the most important 
decidual secretory products, with important roles at the embryo-maternal 
interface in the regulation of placental development (Matsumoto et al., 2008), 
embryo implantation (Irwin & Giudice, 1998) and fetal growth (Ben Lagha et al., 
2006).  Inhibin A is produced by the corpus luteum during the luteal phase of 
the ovarian cycle (Muttukrishna et al., 1994) and is also produced by the 
syncytiotrophoblast in early pregnancy.  The clearance of inhibin A is fast with a 
short half-life of around 45 minutes (Muttukrishna et al., 1997).  Inhibin pro-αC 
is produced by the corpus luteum (Lockwood et al., 1997) and is thought to play 
a role as a paracrine and endocrine regulator of placental function.  These 
markers may be useful in monitoring the luteal-trophoblastic axis in pregnancy.  
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Elson et al. (2005a) found that the presence of a raised level of IGFBP-1 and 
low levels of inhibin A were associated with an increased chance of successful 
expectant management of miscarriage.  Inhibin A has also been used to predict 
pregnancy loss in women with recurrent miscarriage (Muttakrishna et al., 2002), 
IVF pregnancies (Hauzman et al., 2004), and threatened miscarriage (Johns et 
al., 2007).  Kirk et al. (2009) found that serum inhibin A levels may be useful in 
predicting failing PULs.   
We have hypothesised that by combining clinical information, ultrasound 
findings and these newer biochemical markers we could predict the 
spontaneous resolution of pregnancies of unknown location.  The aim of this 
study was to test this hypothesis. 
 
5.2 SUBJECTS & METHODS 
This was a prospective observational study of 129 women from Sunderland 
Royal Hospital, Sunderland, and King’s College Hospital, London.  Clinically 
stable women with a positive pregnancy test (Clearview HCG IITM) and no 
evidence of an intrauterine or extrauterine pregnancy on transvaginal scan were 
eligible to take part.  Patients who chose to take part were provided with an 
appropriate information leaflet, oral explanation and a consent form by one of 
the investigative team.  A sample of blood was taken, spun and frozen in the 
laboratory and analysed for hCG, progesterone, inhibin A (Diagnostic Systems 
Laboratories, USA), inhibin proαC (Oxford Bio-Innovation, Oxford, UK) and 
IGFBP-1 (Diagnostic Systems Laboratories, USA).   
 
Women were managed in accordance with the relevant unit policy. These are 
based on the measurement of serum progesterone and β-hCG levels as 
outlined in Table 10.  Follow-up was continued until the pregnancy had 
spontaneously resolved, viability was confirmed or other treatment was 
required.  Clinical data was collected from patient’s medical records and the 
hospital patient database.   
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Progesterone 
(nmol/L) 
hCG (IU/L) Likely diagnosis Follow-up 
<20 >25 Resolving 
pregnancy 
Urine pregnancy 
test in 7 days 
20-60 >25(<1000) High risk of ectopic Serum hCG in 2 
days 
>60 <1000 Normal pregnancy Repeat scan when 
hCG > 1000 
>20 >1000 Ectopic Repeat scan ASAP 
+/- laparoscopy  
 
Table 10.  Protocol used for management of women with PUL 
 
5.2.1  Sample size 
Eight variables were used in the regression analysis and therefore the sample 
size calculated allowed for 10 events per variable i.e.: at least 80 pregnancies 
(Altman, 1999).  
 
5.2.2  Statistical analysis 
 A database was established to record the women’s age, parity, number of 
previous early pregnancy losses, gestational age from menstrual dates, the 
presence of pain and bleeding, endometrial thickness as measured on 
ultrasound, serum biochemical measurements, pregnancy outcomes and time 
to diagnosis and resolution of the pregnancy.  The outcomes were dichotomised 
into ‘spontaneous resolution of PUL’ and ‘other outcome’ categories and 
statistical analyses were carried out using SPSS version 16.0 (SPSS, Chicago, 
IL, USA).  Normality was tested and comparison of means of continuous 
variables was performed using Mann-Whitney or Student t-tests depending on 
data distribution.  Proportions were compared using Yates corrected χ2 test.  A 
value of P < 0.05 was considered statistically significant.   
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A decision tree was developed using the classification and regression trees 
method.  The stopping rules for the iterative process were that the tree should 
have a maximum of five levels, a minimum of five cases were to be present for 
a split to be calculated and any given split should not generate a group with less 
than two cases.  These allow sequential analysis of variables to predict whether 
the PUL would spontaneously resolve or not.  
The multivariate logistic regression analysis was performed with spontaneous 
resolution as the dependent variable.  The objective of the model building 
process was to obtain a “good fit” for the data, with the least number of 
independent variables.   
The regression equation was derived by the forward stepwise selection of 
variables using the likelihood ratio test for determining which variables to 
include in the model.  The goodness of fit for the model was tested using the 
Hosmer and Lemeshow test.  A non-significant P-value (0.978) suggested a 
favourable goodness of fit.  
Substitution into the regression model with actual values for each case allowed 
the calculation of the probability of spontaneous resolution for each individual.  
 Receiver operating characteristic (ROC) curves were then constructed to 
describe the relationship between the sensitivity and false-positive rate for 
different values of these probabilities, and area under the ROC curves (AUC) 
were computed.   
 
5.3 RESULTS 
129 women with a positive pregnancy test and no evidence of an intra-uterine 
or extra-uterine pregnancy on transvaginal scan consented to take part in the 
study.  Data sets were incomplete in 20 cases and these were excluded from 
further analysis.  Of the 109 cases included in the data analysis, 77 (71%) were 
recruited from Sunderland Royal Hospital, Sunderland, and 32 (29%) from 
King’s College Hospital, London.  
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Figure 16.  PUL Study recruitment flow chart.  
 
Of the remaining 109 women, 10 (9%) were asymptomatic and 99 (91%) had 
abdominal pain (62%) and/or vaginal bleeding (92%).  The characteristics of the 
study group in terms of their age, parity and number of previous early 
pregnancy losses are shown in Table 11. 
 
 
Total number PULs recruited = 129 
Complete data sets = 109 
Incomplete data sets = 20 
Spontaneously resolving PULs = 76  Other outcomes = 33 
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Characteristic (n=109)  
Maternal age (years)* 27.6 (7.2) 
Parity# 1 (0-1) 
Early pregnancy losses# 0 (0-1) 
*Data distributed normally with values given as the mean and 
standard deviation; #data distributed non-parametrically with 
values given as the median  (25th to the 75th interquartile range).   
Table 11. Maternal characteristics 
 
Of the 109 women 91% did not require any further treatment and 9% did require 
medical (3%) or surgical (6%) intervention.  The majority (70%) were 
retrospectively labelled as spontaneously resolving PULs i.e. the pregnancy 
was never visualised on TVS and resolved spontaneously.  These took 7-18 
days to spontaneously resolve (median 7 days) i.e. for the urinary pregnancy 
test to become negative.  The final clinical diagnoses made for all of the cases 
and the time taken to make the diagnoses are shown in Table 12. 
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Clinical diagnosis Number (%) Time to diagnosis (days) 
Resolving PUL 76 (70%) N/A 
Persistent PUL# 2 (2%) 15. 5 (13-18) 
Miscarriage* 7 (6%) 16. 3 (8. 3) 
Ectopic pregnancy# 8 (7%) 6 (2. 3-9. 5) 
Viable IUP* 16 (15%) 13. 1 (5. 6) 
*Data distributed normally with values given as the mean and standard deviation; #data 
distributed non-parametrically with values given as the median  (25th to the 75th interquartile 
range).   
 
Table 12.  Clinical diagnoses at completion of follow-up and time to 
diagnosis 
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Outcome Variable 
Spontaneous 
resolution 
n=76 
Other outcomes 
n=33 
P 
hCG (IU/L)# 242 (47.3-87) 573 (276-1478) 0.002 
Progesterone (nmol/L)# 5 (3.28-7.38) 46 (30.10-81.4) <0.001 
Inhibin A (pmol/L)# 7.65 (0-16.207) 16.6 (11.39- 30.47) <0.001 
Inhibin ProαC (pmol/L)# 178.7 (77.2-353.0) 200.0 (90-564.8) 0.112 
IGFBP1 (µg/L)# 13.41 (8.09-23.72) 7.0 (3.91-14.79) 0.02 
Maternal age (years)* 27.1 (7.79) 28.6 (5.6) 0.27 
Gestational age (weeks)* 7.46 (2.42) 5.8 (2) 0.01 
ET (mm) # 7.3 (5.02-10.95) 10.0 (6.8-15.10) 0.04 
*Data distributed normally with values given as the mean and standard deviation; #data 
distributed non-parametrically with values given as the median  (25th to the 75th interquartile 
range).   
 
Table 13.  Comparison of measured variables in spontaneous resolution 
and other outcomes 
 
Table 13 shows the different variables in women when compared according to 
outcome.  There were significant differences in serum hCG, progesterone, 
inhibin A and IGFBP-1 levels, and in gestational age and endometrial thickness 
between women who required further treatment and those who did not.  This 
was not affected by adjusting the progesterone levels for the difference in 
assays.  There was no significant difference between the pre and post adjusted 
progesterone data sets. 
None of the women suffered from excessive vaginal bleeding or required blood 
transfusion.  A patient who presented with bleeding at 6 weeks gestation and 
had an endometrial thickness of 13 mm required a laparotomy and admission to 
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ITU with a septic miscarriage 23 days later.  There was one case of ruptured 
ectopic pregnancy which was diagnosed 8 days after initial presentation with 
serum progesterone level of 8 nmol/L and hCG 945 IU/L.  This was managed 
laparoscopically.  
Serum progesterone was found to have a statistically significant coefficient and 
was therefore included in a logistic regression model.  Natural logarithm of 
serum progesterone levels was used to achieve conformity to linear gradient.  
The probability of successful expectant management was then calculated using 
the formula:  
Probability of spontaneously resolving PUL = 1/(1+e-z) 
Where z = 1. 998 x lnprog – 6. 126 
With this model, at a cut-off value of 10% probability of spontaneous resolution, 
prediction of spontaneous resolution was made with sensitivity of 72% (95% CI 
61-82) and specificity of 94% (95% CI 85-102).  A comparison of ROC curves 
(see Table 14 and Figure 17) showed that the serum progesterone alone 
performs significantly better than the logistic regression model and all other 
individual parameters.  
The novel biochemical markers were not useful in the decision tree analysis for 
predicting spontaneous resolution of PULs (see Figure 18).  The decision tree, 
which includes serum progesterone and hCG levels, predicts 94% of 
spontaneous resolution (sensitivity 99%, specificity 73%, positive predictive 
value 89%, negative predictive value 96%).  
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Variable AUC Standard Error P 
hCG 0.686 0.052 0.002 
Progesterone  0.926 0.029 <0.001 
Inhibin A # 0.714 0.056 <0.001 
Inhibin ProαC  0.607 0.061 0.80 
IGFBP1 # 0.343 0.061 0.011 
LR progesterone 0.914 0.031 <0.001 
 
Table 14.  Results of AUC analysis for the use of different hormonal 
variables to predict spontaneous resolution of PUL.  
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Figure 17.  Receiver Operating Characteristics curves demonstrating the 
performance of the biochemical markers and the logistic regression 
model in their ability in predicting correctly which pregnancies will 
resolve without the need for intervention.  
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Figure 18.  Decision tree analysis for expectant management of PUL 
Final outcome (n = 109) n   (%) 
Spontaneous resolution 76  (69. 7) 
Other outcomes  33  (30. 2) 
 
Progesterone ≤ 21. 8 nmol/L 
n = 78 
Progesterone > 21. 8 nmol/L 
n = 31 
                              n  
Spontaneous resolution    72 (92%) 
Other outcomes  6 (8%) 
 
Low-risk follow-up 
Pregnancy test in 7 days 
 hCG ≤ 181 IU/L 
n = 6 
hCG > 181 IU/L 
n = 25 
Continued follow-up 
hCG in 48 hours 
                              n  
Spontaneous resolution     4 (13%) 
Other outcomes  27 (87%) 
 
                              n  
Spontaneous resolution 3 (50%) 
Other outcomes  3 (50%) 
 
                              n  
Spontaneous resolution    1 (4%) 
Other outcomes  24 (96%) 
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5.4 DISCUSSION 
Our study has confirmed that the majority of women with a PUL have a 
spontaneously resolving pregnancy that is never identifiable on USS and 
requires no further intervention.  The proportion of women with spontaneously 
resolving PULs was 70%, which is similar to the rates found in previous studies 
(Banerjee et al., 2001; Condous et al., 2004).  The frequencies of normal 
intrauterine pregnancies, miscarriages and ectopic pregnancies and our 
intervention rate were also similar to those in previous reports (Banerjee et al., 
2001; Condous et al., 2004).   
The aim of this study was to investigate the usefulness of novel biochemical 
markers in the role of predicting spontaneous resolution of PULs.  The results 
presented show that serum progesterone concentrations are still the best single 
predictor of spontaneous resolution and therefore those pregnancies that 
require no further intervention.  There is however no difference in serum 
progesterone between the intrauterine and ectopic pregnancy groups, which 
adds to the large body of evidence that serum progesterone levels are not 
useful in predicting the location of a pregnancy.  
Inhibin A was found to be the next most useful marker of spontaneously 
resolving PULs after progesterone.  All pregnancies with an inhibin A less than 
or equal to 11 pmol/L were spontaneously resolving PULs, reflecting either 
reduced amount of trophoblast or non-functioning trophoblast.  Inhibin A seems 
to reflect the trophoblast dynamics more accurately than hCG which may be 
due to its shorter half-life.  These findings are consistent with that of Elson et al. 
(2005a) who found that in the expectant management of miscarriage, 
unmeasurable inhibin A was strongly associated with successful expectant 
management.  
 In their recent study Kirk et al. (2009) also found that inhibin A levels were 
significantly lower in spontaneously resolving PULs than in intrauterine or 
ectopic pregnancies.  In this study they found inhibin A levels to be a stronger 
predictor of failing PUL than we have, although this difference is likely to be 
explained by the smaller proportion of failing PULs in their cohort and their use 
of missing value imputation in their statistical analysis.  In both studies novel 
biochemical markers were not better at predicting PUL outcome than 
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progesterone, and like hCG, inhibin A levels were not useful at predicting the 
location of a pregnancy.   
To our knowledge this is the first time that IGFBP-1 and inhibin proαC levels 
have been investigated in the management of PUL.  Two theories exist for the 
role of IGFBP-1 in early placentation.  One is that higher levels of IGFBP-1 
inhibit binding of the trophoblast to the decidua, the other that there is 
overproduction of IGFBP-1 by the decidua in response to defective 
implantation.  In miscarriage high levels are associated with an increased 
chance of successful expectant management (Elson et al., 2005a).  It is thought 
that the high levels of IGFBP-1 reflect a defect in the attachment of the 
trophoblast to the decidua and thus an increased chance of spontaneous 
expulsion of retained products of conception.  In our study IGFBP-1 tended to 
be higher in the spontaneously resolving PULs than in other outcome groups, 
although not significantly so.  IGFBP-1 was less than or equal to 16 ng/mL in 
every PUL which was subsequently found to be a viable intrauterine pregnancy.  
This again suggests that high levels of IGFBP-1 reflect defective implantation.   
We have not found inhibin proαC levels to be helpful in differentiating 
spontaneously resolving PULs from those that need further investigation.  
Inhibin proαC is known to be a produced by the corpus luteum (Fowler et al., 
1998) and levels fall after administration of mifepristone in termination of 
pregnancy (Lahiri et al., 2003).  It has been suggested that inhibin proαC may 
be responsible for maintaining luteal production of progesterone.  We would 
therefore expect lower levels to be associated with spontaneously resolving 
PULs but our findings have not confirmed this.     
Persisting PULs are PULs where the serum hCG levels fail to decline, where 
there is no evidence of trophoblast disease, and the location of the pregnancy 
cannot be identified by ultrasound or laparoscopy.  In general the serum hCG 
levels are low (<500 IU/L) and have reached a plateau.  Such cases have been 
successfully treated with methotrexate (Condous et al., 2004).  Biochemistry 
(hCG and progesterone) has been shown not to be reliable for predicting 
persisting PUL (Condous et al., 2002).  We had only two cases of persistent 
PUL in our series.  We were therefore unable to make any conclusions 
regarding the usefulness of the novel biochemical markers in this group.  As 
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persisting PULs are relatively uncommon, a large multicentre study would be 
required to investigate this further.  
In this study novel markers of the luteal-trophoblastic axis have not been more 
useful than traditional markers in the identification of spontaneously resolving 
PULs.  Unlike miscarriages, PULs are a heterogenous group including both 
viable and failing intrauterine and extrauterine pregnancies.  A high 
progesterone level reflects a normally functioning corpus luteum and placenta of 
a viable pregnancy (Banerjee et al., 1999) which can occur in both intrauterine 
and ectopic pregnancies.  We have confirmed that in PULs a low progesterone 
level indicates a failing corpus luteum and therefore a spontaneously resolving 
pregnancy.  As the newer markers may more specifically reflect the functioning 
of the trophoblast, differences between the various specific types of pregnancy 
may have been lost in the analysis as ‘spontaneously resolving PULs’ and 
‘other outcomes’.  Numbers of cases within the outcomes grouped together as 
‘other’ were too small to allow individual analysis.  In the expectant 
management of PUL however, the clinically important division is between 
pregnancies that are spontaneously resolving and those that need further 
investigation.  
Endometrial thickness was significantly lower and gestational age significantly 
higher in the spontaneously resolving PULs compared to the other outcome 
groups.  It has previously been shown that chorionic villi may be present in 69-
100% of miscarrying women with an endometrial thickness of less than 5 mm 
(Rulin et al., 1993, Kurtz et al., 1991).  It would appear that in PULs, as in 
miscarriages, the smaller amount of trophoblast present is associated with 
spontaneous resolution of the pregnancy.   
PULs which are early viable intrauterine pregnancies are not visible on scan 
because they are too small to visualise as a result of their early gestational age.  
If a pregnancy is a PUL at an increased gestational age then it is more likely to 
be an abnormal pregnancy.  This explains the increased gestational age in the 
spontaneous resolution group.   
Day et al. (2009) have recently proposed a modified clinical protocol for the 
management of PUL.  They have shown that clinically stable patients with a 
serum progesterone level of less than 10 nmol/L can be safely discharged from 
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active follow-up after their initial visit.  In our study we had 63 such cases.  
Although 59 (94%) of these did resolve spontaneously, three cases of ectopic 
pregnancy and one miscarriage were subsequently diagnosed, all of which 
required further intervention.  We would therefore recommend that follow-up 
pregnancy tests continue to be performed to allow identification of these cases.  
Decision tree analysis is a useful clinical decision making tool and forces 
decision-makers to make the bases for their decisions explicit (Thornton, 1990).  
The decision tree analysis as described in this study provides information that 
can be used both for patient selection and counselling.  Using this approach 
every clinically stable women with a PUL would have their follow-up strategy 
decided based on initial hCG and progesterone, minimizing the need for repeat 
blood-sampling at 48 hours, as in the two-stop hCG ratio model favoured by 
Condous’ group.  This would reduce visits, delay, and patient anxiety whilst the 
second hCG result is awaited.  It may also be more cost effective, with no 
reduction in sensitivity.  
 
5.5 CONCLUSION 
In this study we have shown that inhibin A, IGFBP-1 and inhibin proαC, novel 
biochemical markers of the luteal-trophoblastic axis, are not clinically useful in 
the prediction of spontaneous resolution of PULs.  Our data confirm that serum 
progesterone is the best single marker, and that a model using a combination of 
serum hCG and progesterone is the most effective approach to predict 
spontaneous resolution of PULs in a single visit.  Further investigation is 
needed into the use of novel biochemical markers in the management of more 
specific pregnancy outcome groups such as ectopic pregnancies.  
 95 
 
5.6 SUMMARY OF PREDICTION OF SPONTANEOUS RESOLUTION OF PUL 
USING NOVEL BIOCHEMICAL MARKERS 
• The novel biochemical markers inhibin A, IGFBP-1 and inhibin proαC are 
not clinically useful in the prediction of spontaneous resolving PULs.  
• Serum progesterone remains the best single marker for predicting 
spontaneously resolving PULs.  
• A model using a combination of serum hCG and progesterone is the 
most effective approach to predict spontaneous resolution of PULs in a 
single visit.  
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CHAPTER 6.  PREDICTION OF SUCCESSFUL EXPECTANT 
MANAGEMENT OF MISCARRIAGE AND ECTOPIC PREGNANCY 
USING NOVEL BIOCHEMICAL MARKERS   
6.1 INTRODUCTION 
Early pregnancy complications include miscarriage, ectopic pregnancy and 
pregnancy of unknown location (PUL).  In recent years the management of 
these patients has changed with a shift in focus from a surgical approach to one 
based on an expectant or ‘watch and wait’ policy (RCOG, 2006).  PUL will not 
be discussed further in this chapter as it is dealt with in full in Chapter 5.  
 
6.1.1 Miscarriage 
Miscarriage is a common problem with approximately one in seven confirmed 
pregnancies ending in miscarriage in the first trimester (Regan et al., 1989) and 
accounts for approximately 50 000 inpatient admissions in the United Kingdom 
annually (DoH stats, 2005) (Sagili & Divers, 2007).  Miscarriage and its 
treatment can have both medical and psychological consequences.  While 
maternal death is rare after miscarriage, particularly in the first trimester, it has 
featured in previous Confidential Enquiries into Maternal Deaths in the UK, 
particularly after surgical procedures in association with sepsis.  
Surgical evacuation of retained products of conception has been the standard 
procedure for patients with incomplete or missed miscarriage for more than 60 
years.  Although still the method of choice when bleeding is excessive, vital 
signs are unstable or infected tissue is present in the uterine cavity, the surgical 
and anaesthetic risks, the psychological distress (Lok & Neugebauer, 2007) and 
the increased cost (Petrou et al., 2006), make it less advantageous in other 
cases.  In the last decade medical management with antiprogesterone and/or 
prostaglandins has become popular with success rates quoted from 40-95% 
(Sagili & Divers, 2007) varying with the regimen used and the type of 
miscarriage.  The commonly used drug misoprostol is not licensed for use in the 
management of miscarriage and side effects include diarrhoea, fatigue and 
vaginal bleeding.  
 97 
Expectant management of miscarriage has been shown to be safe and 
effective.  A review by Butler (2005) showed that expectant management is 
successful within 2-6 weeks without increasing the complications in 80-90% of 
women with incomplete spontaneous miscarriage and 65-75% of women with 
missed miscarriage.  The MIST trial did not show any increase in infection rates 
with expectant management as compared to medical or surgical management, 
rates were low (2-3%) regardless of treatment modality although expectant and 
medical management were associated with a higher number of unplanned 
admissions and unplanned surgical evacuation procedures (Trinder et al., 
2006).   
 
6.1.2 Ectopic Pregnancy 
Ectopic pregnancy is still a major problem in the United Kingdom, with around 
30,000 cases diagnosed annually.  The overall rate of ectopic pregnancy 
(11/1000 pregnancies) and the mortality rate (0.3/1000 ectopic pregnancies) 
had been relatively static in the UK from 1991 to 2005 but had fallen to 
0.17/1000 ectopic pregnancies in the recent maternal mortality report (CMACE, 
2011).  It is hoped that this trend will continue.   
Many ectopic pregnancies detected in modern practice would not have been 
diagnosed in the past and are likely to have resolved without any treatment.  
Historically ectopic pregnancies were diagnosed at the time of surgery, often in 
women who were not aware that they were pregnant.  Now that home 
pregnancy tests can detect hCG levels at less than 25 IU/L, a pregnancy can be 
diagnosed before a menstrual period has been missed and as a consequence 
women present at earlier gestations.  The widespread use of dedicated early 
pregnancy assessment units with high resolution transvaginal ultrasonography, 
allow early diagnosis of pregnancy location and are likely to have contributed to 
this increase in the diagnosis of relatively clinically insignificant ectopic 
pregnancies.  Despite this increase in the sensitivity of non-invasive tests for 
ectopic pregnancy and the detection of very mild forms of the condition, patients 
and clinicians generally still consider ectopic pregnancy to be a life-threatening 
condition.  As a result some sort of therapeutic intervention is usually used 
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whenever the diagnosis of an ectopic pregnancy is made, regardless of the 
clinical presentation.  
 The management of tubal ectopic pregnancy in the presence of haemodynamic 
instability should clearly be by the most expedient method, surgery (RCOG, 
2006).  The options for the treatment of haemodynamically stable women, 
however, also include medical management and expectant management.   
Single dose intramuscular methotrexate is the most commonly used medical 
treatment for ectopic pregnancies in the UK (RCOG, 2004).  Methotrexate is a 
cytotoxic drug that binds to the enzyme dihydrofolate reductase and therefore 
interferes with DNA synthesis and disrupts cell multiplication.  Success rates 
range from 65-95% (Kirk et al., 2006) with the studies varying widely in their 
inclusion criteria.  The reproductive outcomes after methotrexate treatment 
have been studied and one study has shown that overall subsequent 
intrauterine pregnancy rates were higher and ectopic pregnancy rates lower 
after methotrexate than salpingostomy (Fernandez et al., 1998).  Economic 
comparisons have also shown benefits of methotrexate over the surgical 
management of ectopic pregnancies (Mol et al., 1999; Sowter et al., 2001).   
Expectant management of tubal ectopic pregnancies was first evaluated by 
Lund in 1955.  In his series of 119 patients only 68 (57%) were successfully 
treated expectantly and 51 patients required surgery for persistent symptoms or 
large intraperitoneal haemorrhage (Lund, 1955).  This was before laparoscopy 
and ultrasound were available.  
Since then a number of studies, using more stringent inclusion criteria, have 
reported much more successful expectant management of ectopic pregnancies 
(65-95%).  Low hCG levels, a decreasing trend in hCG levels, the absence of 
an ectopic gestational sac and a longer time from the last menstrual period are 
associated with more successful expectant management (Trio et al., 1995; Atri 
et al., 2001).  In one study an hCG level of <1000 IU/L was chosen as the 
optimal cut-off identifying 88% of women whose ectopic pregnancies 
spontaneously resolved (Trio et al., 1995).  In 2004 Elson et al. described 
decision-tree analysis to predict spontaneous resolution of tubal ectopic 
pregnancies and therefore aid selection of appropriate management (Elson et 
al., 2004).  Initial serum βhCG level was again the best individual predictor of 
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outcome (96% success with βhCG </= 175 IU/L) but progesterone level, 
gestational age and average diameter of the ectopic were used to predict 
spontaneous resolution where initial βhCG >175 IU/L.  
Expectant management has important advantages over medical treatment as it 
follows the natural history of disease and is free from the serious side effects 
associated with methotrexate and the surgical risks of surgery.  The original 
purpose of expectant management of ectopic pregnancy was the preservation 
of fertility although there is yet no randomised study comparing fertility outcome 
after expectant management with conservative surgical and medical 
management observational studies suggest that rates are comparable (Kirk et 
al., 2006).  RCOG guidance now suggests that expectant management is a 
useful form of treatment for ectopic pregnancy in selected cases (RCOG, 2004).  
This option is therefore limited to a very small proportion of ectopic pregnancies 
and success rates vary widely between centres (Cohen & Sauer, 1999).  
One of the difficulties with expectant management of miscarriage and ectopic 
pregnancy is the lack of selection criteria which reliably predict the likelihood of 
successful spontaneous resolution of pregnancy and therefore successful 
expectant management.  In 2005 Elson et al., found that biochemical markers 
(including serum hCG, progesterone, inhibin A, IGFBP-1 and inhibin proαC) 
show significant differences in miscarriages and failed pregnancies (including 
miscarriages and ectopic pregnancies) that resolve spontaneously, as 
compared with those that do not (Elson, 2005b).  We have hypothesised that 
the decision-trees developed by Elson (2005b) will predict spontaneous 
resolution of miscarriages and failed pregnancies in our population.  Our aim 
was to test this hypothesis.  
 
6.2 STUDY DESIGN 
This was a prospective observational study over 2 years of women with a 
diagnosis of miscarriage or ectopic pregnancy identified on ultrasound scan.  
Women were referred to the dedicated Early Pregnancy Assessment Unit 
(EPAU) at Sunderland Royal Hospital or King’s College Hospital by their 
general practitioners or hospital consultants because of suspected early 
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pregnancy complications, or self-referred because of previous early pregnancy 
losses.  All women had a positive urine pregnancy test (Clearview HCG IITM, 
Unipath, Bedford, UK).  A full history was documented by the EPAU nurse and 
an ultrasound scan was then carried out by the dedicated EPAU sonographer 
using a high-frequency transvaginal probe.  
A diagnosis of a missed miscarriage was made based on one of the following 
criteria: 
(i) the gestational sac was greater than 20 mm in diameter with no intrauterine 
contents;  
(ii) the fetal crown rump length was greater than 10 mm with no fetal heart rate 
detected;  
(iii) the gestational sac had failed to develop from a previous scan more than 10 
days ago.   
An incomplete miscarriage was diagnosed in women with a history of bleeding 
in whom an intrauterine gestational sac had been previously seen on scan or 
where there was absence of an intact gestational sac and the presence of any 
amount of visible trophoblast in the uterine cavity.  The sonographic features of 
visible trophoblast are irregular echoes in the midline of the uterine cavity.   
A diagnosis of tubal ectopic pregnancy was made when a mass with ultrasound 
appearance of an ectopic pregnancy was seen in either adnexa, separate from 
the ovary and corpus luteum.    
Clinically stable women with a miscarriage or ectopic pregnancy who met 
departmental eligibility criteria for expectant management were eligible to take 
part (see Table 15 and Figure 19).  Patients who chose to take part were 
provided with an appropriate information leaflet, oral explanation and a consent 
form by one of the investigative team.  Routine and study blood samples were 
taken together.  hCG and progesterone were measured immediately, and 
another sample was spun and frozen in the laboratory and later analysed for 
17α-hydroxyprogesterone (Diagnostic Systems Laboratory, USA), inhibin A 
(Diagnostic Systems Laboratory, USA), inhibin proαC (Oxford Bio-Innovation, 
Oxford, UK) and IGFBP-1 (Diagnostic Systems Laboratory, USA).   
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Expectant management of miscarriage 
• USS evidence of an intrauterine incomplete or missed miscarriage 
• <12 weeks gestation 
• No evidence of cardiovascular compromise, active bleeding or 
pyrexia 
• No complicating medical disorders (Hb <10g/dL, 
immunosuppression, coagulation disorders, concurrent disease 
likely to result in infection) 
• Informed consent with expressed preference for expectant 
management 
Expectant management of ectopic pregnancy 
• <3 cm tubal mass on USS with 
o No FH 
o No yolk sac 
o No intraperitoneal blood 
• βhCG < 1500 IU 
• Patient haemodynamically stable  
• No moderate/ severe pain 
• Informed consent with expressed preference for expectant 
management 
 
Table 15.  Eligibility criteria for expectant management of miscarriage 
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Figure 19.  Flow-chart illustrating Trust Protocol “Management of Tubal 
mass”  
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Women were managed in accordance with the appropriate unit policy. Follow-
up was continued until the pregnancy had spontaneously resolved or other 
treatment was required.   
In the miscarriage arm women were reviewed at 3 weeks and if the gestational 
sac was still present on USS they were given the option of continuing with 
expectant management or proceeding with medical or surgical evacuation.  If 
continuing with expectant management they were reviewed again a further 3 
weeks later and if the gestational sac was still present on USS they were 
advised to proceed with medical or surgical evacuation.  In the ectopic 
pregnancy arm of the study, follow-up was continued until the serum hCG was 
less than 20 IU/L, samples taken at 48 hours, twice weekly for two weeks and 
then weekly.  Expectant management was discontinued if a woman had severe 
pain or serum hCG was not declining.  All women were given open access to 
the gynaecological ward and the telephone number.  Expectant management 
was discontinued if the women complained of increasing abdominal pain or 
hCG did not decline on follow-up measurements.  
Clinical data was collected from patient’s medical records and the hospital 
patient database and recorded in a Microsoft Excel spreadsheet.   
 
6.2.1 Statistical analysis 
 Databases was established to record the women’s age, parity, number of 
previous early pregnancy losses, gestational age from menstrual dates, the 
presence of pain and bleeding, ultrasound findings, serum biochemical 
measurements, expectant management outcomes, time to resolution of the 
pregnancy and complications.  The outcomes were dichotomised into 
‘successful expectant management’ and ‘failed expectant management’ 
categories and statistical analyses were carried out using SPSS version 16.0 
(SPSS, Chicago, IL, USA).  Comparison of means of continuous variables was 
performed using Mann-Whitney or Student’s–t tests depending on data 
distribution.  Proportions were compared using the Yates corrected χ2 test.  A 
value of P < 0.05 was considered statistically significant.  Results were entered 
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into Elson et al’s original decision-trees, and the sensitivities and specificities 
calculated.   
6.3 RESULTS 
Study recruitment is summarised in Figure 20.  42 women with a diagnosis of 
miscarriage were identified on ultrasound scan, opted for expectant 
management and consented to take part in the study.  These were all patients 
at Sunderland Royal Hospital.  In seven women data was incomplete and they 
were therefore excluded from further analysis.  Of the remaining 35 women, 29 
(82%) had successful expectant management, three (9%) went on to have 
medical treatment, and three (9%) had a surgical evacuation.  Two women had 
emergency admissions to the gynaecology ward: one patient woman was 
admitted with a collapse and had an emergency surgical evacuation; another 
was admitted with pain and collapse but did not require any further treatment.  
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Total number miscarriages 
recruited = 42 
Complete data sets = 35 
Incomplete data sets = 7 
Successful expectant 
management = 29 
Unsuccessful expectant 
management = 6 
Total number ectopics 
recruited = 11 
Complete data sets = 9 
Incomplete data sets = 2 
Successful expectant 
management = 4 
Unsuccessful expectant 
management = 5 
Miscarriages Ectopic Pregnancies 
Figure 20.  Miscarriage and ectopic pregnancy study recruitment flow chart.  
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An initial diagnosis of a missed miscarriage was made in 27 (77%) and of 
incomplete miscarriage in 8 (23%).  The median time to pregnancy resolution 
was 21 days (25th-75th interquartile range 20-24).   
Only eleven women with a diagnosis of ectopic pregnancy were identified on 
ultrasound scan, were suitable for and opted for expectant management, and 
consented to take part in the study.  In two of these women data was 
incomplete and so they were excluded from further analysis.  Of the remaining 
nine women five (56%) were recruited from King’s College Hospital, and four 
(44%) from Sunderland Royal Hospital.  Expectant management was 
successful in 4 cases (44%), and further treatment was required in five cases 
(56%).  Three of these had surgery (all laparoscopically) and two had medical 
management with methotrexate.  No serious complications occurred.  The 
median mean mass diameter was 18 mm (25th-75th interquartile range 10-20).  
The mean time to resolution of the pregnancy was 13.1 days (SD 7.3).  
Progesterone levels were adjusted for the difference between the assays and 
Mann-Whitney U tests confirmed no statistically significant difference. 
Table 16 and Table 17 show the measured variables in the miscarriage and 
ectopic pregnancy sets when compared by expectant management outcome.  
The only statistically significant difference between the successful and failed 
expectant management groups was serum hCG levels in the ectopic pregnancy 
set.   
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Outcome Variable 
Successful 
expectant 
management  
n=29 
Failed expectant 
management 
n=6 
P 
Maternal age (years) # 33 (25-38.5) 30.5 (21.8-35.5) NS 
Parity# 1 (0-2) 1 (0-3) NS 
Gestational age (weeks) * 10 (1.6) 9 (2.3) NS 
Previous early pregnancy 
losses 
0 (0-1) 0 (0-1) NS 
Incomplete miscarriages 
(%)** 
17 32 NS 
Vaginal bleeding (%)** 83 97 NS 
Mean diameter POC (mm) # 16.3 (9-23) 20.6 (16.6-26.4) NS 
hCG (IU/L)# 3270 (606-7830) 8256 (2483-
30944) 
NS 
Progesterone (nmol/L)# 1.7 (5.3-2.0) 22.5 (15.0-559.5) NS 
Inhibin A (pmol/L)# 24.7 (2.0-44.7) 86.6 (24.0-118.2) NS 
Inhibin ProαC (pmol/L)# 190.3 (152.3-
260.4) 
176.7 (123.9-
256.0) 
NS 
IGFBP1 (µg/L)# 27.6 (16.1-36.7) 28.4 (9.6-52.2) NS 
17-OHP (ng/mL) # 0.43 (0.12-0.77) 0.41 (0.15-1.1) NS 
*Data distributed normally with values given as the mean and standard deviation; #data 
distributed non-parametrically with values given as the median  (25th to the 75th interquartile 
range).  **discrete data given as percentage of feature for each final outcome.  
 
Table 16.  Comparison of measured variables in miscarriages with 
successful and failed expectant management  
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Outcome Variable 
Successful 
expectant 
management  
n=4 
Failed expectant 
management 
n=5 
P 
Maternal age (years) * 28.3 (7.2) 34.4 (6.5) NS 
Gestational age (weeks) * 10 (1.6) 9 (2.3) NS 
Parity# 0 (0-1) 1 (0-2) NS 
Previous early pregnancy 
losses 
0 (0-2) 0 (0-2) NS 
Vaginal bleeding (%)** 75 0 NS 
Pain (%)** 25 60 NS 
Mean diameter mass (mm) # 15. 5 (8. 5-21) 18 (10-20) NS 
hCG (IU/L)# 56 (42-258) 1497 (661-2063) 0.014 
Progesterone (nmol/L)# 6. 9 (5. 2-22. 3) 27 (19. 9-45.6) NS 
Inhibin A (pmol/L)# 0 (0-0) 0 (0-7) NS 
Inhibin ProαC (pmol/L)# 67 (15-421) 253 (54-691) NS 
IGFBP1 (µg/L)# 6.5 (2.8-24.4) 6.9 (5.5-44.4) NS 
*Data distributed normally with values given as the mean and standard deviation; #data 
distributed non-parametrically with values given as the median  (25th to the 75th interquartile 
range).  **discrete data given as percentage of feature for each final outcome.  
 
Table 17.  Comparison of measured variables in ectopic pregnancies with 
successful and failed expectant management  
 
There was no significant difference in time to resolution by expectant 
management outcome in either the miscarriage or ectopic pregnancy sets.  In 
expectant management of miscarriage the median time to spontaneous 
resolution was 21 days (25th-75th interquartile range 20.5-21.5) and 31 days 
(25th-75th interquartile range 12.5-43.5) in the failed expectant management 
group.  In the expectant management of ectopic pregnancies median time to 
pregnancy resolution was 11 days (25th-75th interquartile range 7.25-14) in the 
successful group and 16.5 days (25th-75th interquartile range 5.75-24.25) in the 
group which required further treatment.  
 109 
6.3.1 Miscarriages 
When our data are put into Elson et al’s miscarriage decision tree (Elson, 
2005a; 2005b) (see Figure 21), successful expectant management is predicted 
with a sensitivity of 86% (95% CI 74-99) and a specificity of 29% (95% CI 5-62) 
with a PPV of 83% (95% CI 3-64) and NPV 33% (95% CI 4-71).  91% of cases 
with an unmeasurable inhibin A level were successfully managed expectantly, 
compared with 95% in the original study.  With higher levels of inhibin A 76% 
had successful expectant management, compared with 51.5% in the original 
study.  
 
6.3.2 Failed pregnancies 
When our miscarriage and ectopic pregnancy data are used together in Elson’s 
failed pregnancy decision tree (Elson, 2005b) (see Figure 22), successful 
expectant management is predicted with a sensitivity of 88% (95% CI 76-99) 
and a specificity of 17% (95% CI 4-38) with a PPV of 74% (95% CI 3-64) and 
NPV 33% (95% CI 4-71).  If hCG < 1800 IU/L then the chance of successful 
expectant management is 88%, compared with 89% in Elson’s original study.  
When the hCG > 1800 IU/L the chance of successful expectant management is 
69%, compared with 44% in the original study.   
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Successful expectant management 29 (37) 
Failed expectant management   6 (17) 
 
Inhibin A 
<=3.9 <>3.9 
Successful 8 (20) 
Failed  0 (1) 
Successful 21 (17) 
Failed  6 (16) 
For expectant management 
Watch for occasional failure 
<=15 
 
Successful 4 (3) 
Failed  2 (9) 
Successful 17 (14) 
Failed  4 (7) 
For surgery 
Inhibin pro αC 
<=400 >400 
 
Successful 17 
(10) 
Failed  4 (2) 
 
Successful 0 (4) 
Failed  0 (5) 
 
For expectant management 
Watch for occasional failure 
For expectant management 
High chance of failure 
IGFBP-1 
>15 
Decision tree developed by 
Elson (2005b) with original 
numbers shown in brackets 
Figure 21. Expectant management of miscarriage decision tree 
decision treedecision tree 
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Successful 20 (15) 
Failed  8 (19) 
Successful 13 (40) 
Failed  3 (5) 
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Failed  4 (14) 
Successful 15 (12) 
Failed  4 (5) 
Successful    0 (2) 
Failed       0 (1) 
Successful   4 (1) 
Failed     4 (13) 
Successful    15 (9) 
Failed       4 (1) 
Successful    0(3) 
Failed       0 (4) 
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>25 <=25 <=15 
Gestational 
age 
For expectant 
management 
High chance of failure 
Successful expectant management 33 (55) 
Failed expectant management    11 (24) 
 
Decision tree 
developed by Elson 
(2005b) with 
original numbers 
shown in brackets 
Figure 22. Expectant management of failed pregnancies decision tree 
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6.4 DISCUSSION 
6.4.1 Miscarriages 
In this study 83% of expectant management of miscarriage was successful.  
Previous studies have found success rates ranging from 25% to 91% (Jurkovic 
et al., 1998; Luise et al., 2002) although the type of miscarriage has been found 
to be significant, with pregnancies with an intact gestation sac (i.e. missed 
miscarriages) being less likely to resolve spontaneously.  In Elson’s original 
cohort of 54 cases of expectant management of miscarriage (2005a; 2005b), 
the success rate was 69% with 41% having an initial diagnosis of a missed 
miscarriage.  Our success rate of 83%, with 77% having an initial diagnosis of a 
missed miscarriage, is therefore better than expected.  This may be a result of 
increasing experience and confidence amongst clinicians with the expectant 
management of miscarriage, or changing expectations amongst women with 
miscarriages.   
We did not find that type of miscarriage, or any other factor was significantly 
different between the outcome groups.  Inhibin A and IGFBP-1, used in Elson’s 
original decision tree, were again useful for predicting successful expectant 
management of miscarriages.  This again suggests that low levels of inhibin A 
indicate a small amount of functioning trophoblast (Birdsall et al., 1997; 
Lockwood et al., 1997) and that inhibin A reflects trophoblastic activity more 
accurately than hCG (Hauzman et al., 2004), presumably due to its shorter half-
life.  Elson et al., (2005a) were the first to describe raised levels of IGFBP-1 in 
association with miscarriage and suggested that that high levels of IGFBP-1 
reflect a defect in attachment of the trophoblast to the decidua, thus the 
products of conception are more easily expelled.  This agrees with placental 
work which has found higher levels of IGFBP-1 mRNA in placentas from 
pregnancies complicated by pre-eclampsia, suggesting that IGFBP-1 might be 
associated with impaired trophoblastic invasion (Shin et al., 2003).  Our findings 
do not confirm or disprove this theory.  
Inhibin proαC was not a useful part of the decision tree in our cohort, as in the 
cases with a high inhibin A and IGFBP-1, none had an inhibin proαC RI level of 
more than 400 pmol/L.  Previously Illingworth et al., (1996) found lower levels of 
inhibin proαC-RI to reflect non-viability, and Elson et al., (2005a) found lower 
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levels of inhibin proαC-RI in successful expectant management of miscarriage.  
We therefore expected to see lower levels in the successful expectant 
management group, but this was not demonstrated in our cohort.  
 
6.4.2 Ectopic pregnancies 
Our findings confirm Elson’s original finding that in ectopic pregnancy, serum 
hCG is the only significant variable between successful and failed expectant 
management groups (Elson, 2005b).  In our cohort of ectopic pregnancies, all 
cases with hCG <400 IU/L resolved spontaneously.  Lui et al., (1997), Atri et al., 
(2001), Elson et al., (2005a), Trio et al., (1995) and Korhonen et al., (1994) also 
found lower initial levels of hCG to be associated with increased success of 
expectant management.  Trio et al., (1995) used receiver operating-
characteristics curve analysis to chose hCG < 1000 IU/L as the optimal cut-off, 
and found it to detect 88% of ectopic pregnancies that resolve spontaneously.  
In our cohort the success rate of expectant management when serum hCG 
>1000 IU/L was 0% and when serum hCG < 1000 IU/L was 67%.  Expectant 
management failed however, in two cases with hCG < 1000 IU/L.  
When looking at symptoms we noted that all of our ectopic pregnancies with 
vaginal bleeding were successfully managed expectantly, although this 
difference did not reach statistical significance.  The presence of vaginal 
bleeding has not previously been described as a marker of successful 
expectant management and our findings differ greatly from Elson’s original 
study (2005b) where 100% of the ectopic pregnancies requiring surgical 
intervention had vaginal bleeding.  Our observation may be spurious and 
related to our small numbers, although the presence of bleeding may indicate a 
tubal abortion, and therefore spontaneous resolution.  We also noticed that a 
higher proportion of our failed expectant management group complained of 
pain, although again this was not statistically significant.  It is likely that the 
presence of pain contributed to the decision to proceed with active management 
of the ectopic pregnancy.  This therefore may lead to therapeutic bias in 
interpretation of the results although is reflective of regular clinical practice.   
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Overall our rate of successful expectant management of ectopic pregnancy was 
44%.  Other studies have reported success rates of between 48% and 100% 
(Elson et al., 2004; Ylostalo et al., 1992; Korhonen et al., 1994; Cacciatore et 
al., 1995; Trio et al., 1995; Lui et al., 1997), however, considering our inclusion 
criteria, our success rate was lower than expected.  This again may be biased 
by our small numbers, or may be the result of a lack of experience in expectant 
management of ectopic pregnancy amongst clinicians.   
 
6.4.3 Failed pregnancies  
In Elson et al’s original studies hCG was the best discriminator for successful 
expectant management of a failed pregnancy.  The pregnancies with low hCG 
levels and a small amount of pregnancy tissue on ultrasound scan were the 
most likely to resolve spontaneously, both of these measures reflecting the 
amount of functioning trophoblast.  IGFBP-1 was the next best discriminator 
with high levels reflecting defective attachment to the decidua and an increased 
chance of successful expectant management.  These findings are all confirmed 
in our population.  The rest of the failed pregnancy decision tree is less useful in 
our cohort, however, as the cut-offs of lesions >25 mm, gestational age <42 
days, and inhibin proαC >400 pmol/L were not discriminatory.  
 
6.4.4 Models in the management of early pregnancy failure 
Decision-making regarding the treatment of early pregnancy failure is complex.  
Decision tree analysis produces an easy to follow-pathway which resembles the 
clinical decision making process.  The decision trees can be used for patient 
selection and counselling, thus enabling women to make informed decisions.  
Using the decision tree analysis for the management of miscarriages alone 
successful expectant management could be predicted with sensitivity of 86% 
and specificity of 29%.  This means that it is excellent at predicting those 
women who will have a successful management but not very accurate at 
predicting those whose expectant management will fail.  This decision-tree 
performs nearly as well in our cohort as it did in the cohort from which it was 
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constructed.  It also compares favourably to the logistic regression model 
proposed by Nielsen et al., (1996) based on the traditional markers hCG and 
progesterone, and to the use of colour Doppler as advocated by Schwarzler et 
al., (1999).   
The decision tree for failed pregnancies works less well with our data, with 88% 
sensitivity and only 17% specificity.  This again means that the decision tree is 
good at predicting those women that will have a successful expectant 
management but is poor at predicting those in which expectant management 
will fail.  In the group for which the decision-tree suggests surgery is indicated, 
50% had successful expectant management.   
 
6.5 CONCLUSION 
We have shown that many of the discriminatory steps in Elson’s decision trees 
to predict successful expectant management of failed pregnancies and 
miscarriages are useful in our cohort, despite lack of significant differences 
between the successful and failed expectant management groups.  We have 
seen that the novel biochemical markers inhibin A, inhibin proαC and IGFBP-1 
may be useful in the decision trees, although these are not yet available in 
routine clinical practice.  
 
 6.6 SUMMARY OF PREDICTION OF SPONTANEOUS RESOLUTION OF 
MISCARRIAGES AND ECTOPIC PREGNANCIES USING NOVEL 
BIOCHEMICAL MARKERS 
• The decision trees using novel biochemical markers inhibin A, IGFBP-1 
and inhibin proαC are sensitive but not specific in their prediction of 
spontaneous resolution of miscarriages and failed pregnancies. 
• Serum hCG level remains the best single marker to predict successful 
expectant management of ectopic pregnancy. 
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CHAPTER 7.  DISCUSSION 
The aim of this thesis was to investigate the use of novel biochemical markers 
in the diagnosis and management of early pregnancy complications and models 
for their use in clinical practice have been developed and tested.  Although 
there remains a lack of definitive evidence that novel biochemical markers are 
clinically useful for the diagnosis and management of early pregnancy problems 
in current practice, our data suggests that further research is necessary. 
 
7.1 METHODOLOGICAL CHALLENGES 
There are many methodological challenges when designing and conducting 
research in patients with early pregnancy problems.  The diagnosis of a 
miscarriage, ectopic pregnancy or a PUL is a distressing and potentially 
traumatic time for a woman.  At the time of diagnosis there is a large amount of 
clinical information to take in and decisions to make, many women feel unable 
or unwilling to consider taking part in research for these reasons.  The 
symptoms of bleeding and pain in early pregnancy are very common and can 
be very worrying for women, as a result many attend emergency services and 
so not all are seen initially at Early Pregnancy Assessment Units, this can lead 
to suitable cases being missed.  The large number of patients assessed in Early 
Pregnancy Assessment Units makes it challenging for a small research team to 
identify all suitable patients, particularly during weekends and public holidays.  
Excellent working relationships and communication with clinical colleagues are 
essential.   
Expectant management is a fairly novel concept in the management of 
miscarriage and ectopic pregnancy and patients and clinicians have more 
experience with medical and surgical management options.  As a result, due to 
counselling techniques and expectations, even when expectant management 
inclusion criteria are fulfilled, patients often choose to pursue a more active 
course of management.  This has had implications on recruitment for these 
studies.  It already appears however, that this ‘culture’ is gradually changing, as 
patients and clinicians build up more experience in expectant management 
options. 
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In response to difficulties with recruitment for the expectant management of 
PUL and ectopic pregnancy studies, we extended our recruitment to King’s 
College Hospital, London.  This improved our numbers but has introduced other 
issues, which we have done our best to address.  The study populations 
covered by the two recruitment centres differ in a number of ways.  Although 
both are inner-city urban areas with high levels of socioeconomic deprivation, 
the population in Sunderland is fairly static, with a small proportion of ethnic 
minorities whereas King’s College Hospital covers an area with a highly racially 
mixed and mobile population.  Our findings are therefore based on a diverse 
cohort but we cannot infer that they are applicable for general use. 
When recruiting patients from multiple sites it is a concern that the clinical 
management of the patients could differ between them and therefore that site of 
recruitment affects the outcome of treatment.  Although we cannot exclude this 
as a possibility, we think this is unlikely to be a significant problem in our 
studies.  The Early Pregnancy Assessment Units at Sunderland Royal Hospital 
and King’s College Hospital have similar approaches to the management of 
early pregnancy problems and have similar guidelines.  There will of course be 
variation in the application of the guidelines by individual clinicians, but this is 
reflective of clinical practice, and there was no difference in expectant 
management outcome between the two recruitment centres. 
In the PUL and ectopic pregnancy cohorts the hCG and progesterone analysis 
was split between the two recruitment centres, and therefore analysed by 
different methods.  Comparisons of the methods by NEQAS and ourselves 
confirmed that the hCG immunoassays were comparable, and there is a 2 
nmol/L difference between the progesterone assays which did not confer any 
significant difference.  
 
7.2 MODELS IN THE DIAGNOSIS AND MANAGEMENT OF EARLY 
PREGNANCY PROBLEMS 
In this thesis I have developed a decision tree for predicting spontaneously 
resolving pregnancies of unknown location and have tested models for 
predicting successful expectant management of miscarriage and failed 
pregnancy.  When formulating a diagnosis or management plan in clinical 
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practice, a range of factors are combined rather than considered in isolation.  
This process is mirrored in decision-tree analysis, although the decision-making 
steps are explicit and evidence-based. 
For women found to have a ‘pregnancy of unknown location’ it is important to 
balance the importance of reaching a diagnosis with the inconvenience, cost, 
and potential risks associated with follow-up visits and surgical intervention.  
Currently used models for the management of PUL use serum hCG ratios at 0 
and 48 hours, or serum hCG and progesterone levels, to guide further care. The 
use of the decision-tree, as described in Chapter 5, can aid with patient 
selection and counselling. The flow-chart is easy to follow and guides the 
clinician to the appropriate follow-up strategy based on initial hCG and 
progesterone levels.  Patients can be shown the decision-tree so that they can 
understand the basis for the strategy of their care and make informed decisions.  
Using this approach only 23% require ‘high-risk’ follow-up i.e. a repeat blood 
sample in 48 hours, and the remaining 77% have an 89% probability of 
spontaneous resolution.  The need for repeat blood sampling at 48 hours is 
therefore minimized without a reduction in sensitivity. 
Expectant management is a useful alternative to medical or surgical intervention 
in the treatment of miscarriages and ectopic pregnancies.  It is an attractive 
option for women who desire a natural solution and who prefer to avoid 
hospitals, or fear operations.  Many advantages of expectant management have 
been demonstrated, including improved mental health scores in women 
undergoing expectant management of miscarriage (Wieringa-de Waard et al., 
2002), and economic advantages of expectant management of miscarriage 
over traditional surgical management.  The main difficulty with expectant 
management of both miscarriages and ectopic pregnancies, however, is the 
lack of criteria which reliably predict the likelihood of spontaneous resolution of 
the pregnancy, without requiring medical or surgical intervention.  The decision-
tree models developed by Elson (2005b) for the expectant management of 
miscarriage and failed pregnancies use serum levels of traditional and novel 
biochemical markers.  A woman can be given a probability of success based on 
these levels and can therefore make a fully informed decision.  We have tested 
these models and have found them to be useful for predicting successful 
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expectant management in our cohort, despite differences in baseline factors 
between this current study and the original findings.      
The next step in the development of these models is to test them prospectively 
in a range of centres, with implementation carefully audited to allow for the 
differences between ultrasound operators and biochemistry laboratories.  This 
would enable necessary adjustments to be made in order to define the optimal 
cut-offs for each individual unit and the most appropriate model for general use.   
 
7.3 GLYCOSYLATION OF HCG 
Measurements of serum hCG levels are the most commonly used biochemical 
measurement in the management of early pregnancy problems.  We have 
identified variable glycosylation of hCG by lectin-affinity chromatography, with 
changes in expression with gestational age and by pregnancy outcome.  This 
suggests that looking only at levels of hCG is too simplistic, and that by 
analysing the structure of the hCG molecule, in particular the pattern of 
glycosylation, much more useful information could be obtained.  H-hCG, a 
particular isoform of hCG predominant in very early pregnancy, has already 
been found to be useful in the prediction of early pregnancy outcome (Sutton-
Riley et al., 2006).  Using lectin-affinity chromatography to look at the overall 
pattern of glyco-isoform expression has the potential to be a more reliable test, 
and have wider applicability, it also provides a means by which we can increase 
our understanding of the role of hCG isoforms in the physiology of pregnancy. 
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CHAPTER 8.  CONCLUSIONS AND FUTURE RESEARCH 
GOALS 
This thesis describes three studies exploring the use of novel biochemical 
markers in the diagnosis and management of early pregnancy problems: 
Lectin-affinity chromatography reveals five major glyco-isoforms of hCG in early 
pregnancy, the expression of which changes with gestational age and by 
pregnancy outcome.  Further work is required to explore the physiological basis 
of these findings and the applicability of lectin-affinity chromatography as a 
clinical test.   
The novel markers of the luteo-trophoblastic axis inhibin A, IGFBP-1 and inhibin 
proαC are found not to be clinically useful in the prediction of spontaneously 
resolving PULs.  A decision tree model using initial serum hCG and 
progesterone levels is proposed to guide follow-up arrangements.  A larger 
prospective evaluation of this model is required before implementation into 
clinical practice could be recommended.  A large multicentre study could also 
allow the use of inhibin A, IGFBP-1 and inhibin proαC in predicting specific 
outcomes of PULs, to be investigated. 
The decision trees developed by Elson (2005b), using inhibin A, IGFBP-1 and 
inhibin proαC, are found to be useful for predicting spontaneous resolution of 
miscarriages and failed pregnancies.  A large prospective multi-centre study is 
now required to validate these for general implementation.  This could also 
incorporate the multi-centre investigation, which would be needed to recruit 
sufficient numbers, for an observational study into the use of these novel 
biochemical markers in the prediction of spontaneous resolution of ectopic 
pregnancies.  
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PATIENT INFORMATION LEAFLET 
 
 
Study of the value of novel biochemical markers in the prediction of 
successful expectant management of pregnancy of unknown location 
 
We are asking for your help with research that is being conducted in our hospital. 
Before you decide it is important that you understand why the research is being done 
and what it will involve. Please take time to read the following information carefully 
and discuss it with others if you wish. Please ask us if there is anything that is not clear 
or if you would like more information. Take time to decide whether or not you wish to 
take part. Thank you for reading this. 
 
What is the problem? 
You have had an ultrasound scan to check that your pregnancy is developing normally 
today. Unfortunately we are unable to see your pregnancy on scan. This is a pregnancy 
of unknown location. There are three possible reasons for this: 
 
1. A very small normal pregnancy. The pregnancy may be normal, but too small 
to be seen on the scan. This usually happens in women who are unsure of their 
dates or who have long menstrual cycles. 
 
2. A miscarriage. The pregnancy may already have been lost with bleeding and 
cannot be seen on scan. In these cases the pregnancy test may be positive for 
many weeks after the miscarriage. 
 
3. An ectopic pregnancy. The pregnancy may be growing outside the womb 
(uterus). These pregnancies are usually growing in the Fallopian tubes and may 
be difficult to see on scan. Sometimes an ectopic pregnancy can be dangerous 
and this is why we need to monitor you very carefully. 
 
What is the purpose of the study? 
In all women with a pregnancy of unknown location we take blood tests to measure 
pregnancy hormones (βhCG and progesterone) in the blood. This helps us to determine 
which of the above possibilities is most likely. We call this expectant management as it 
allows us to avoid unnecessary invasive tests and treatments in many cases. We think 
that this may be more accurate if we measure some new biochemical markers. These 
markers have been used in the diagnosis and treatment of other early pregnancy 
problems but not in pregnancy of unknown location before. If they are more accurate 
markers we would be able to counsel and treat women with pregnancy of unknown 
location more effectively. 
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Why have I been chosen? 
Every woman who is found to have a pregnancy of unknown location will be 
approached to take part in this study. 
 
 
Do I have to take part? 
Participation is voluntary and you may decide not to take part or withdraw at any time 
without giving a reason. This will not affect your medical care in anyway.    
 
What will happen to me if I take part? 
If you choose to take part in our study a blood sample will be taken for the new 
biochemical markers at the same time as the routine blood tests are taken. No ‘extra’ 
blood tests are required. We will then just observe your progress through until a 
diagnosis is made, and any treatment required is complete. Some of your details 
(including length of pregnancy, ultrasound scan findings, blood test results, diagnosis, 
and any treatments required) will be extracted from your medical records and recorded 
in a research database. Your care will not be any different from normal management, 
apart from the blood sample mentioned above. 
 
Will taking part in the study affect my care? 
As the value of these biochemical markers in investigating pregnancy of unknown 
location has not yet been investigated, these tests will not affect your care in any way. 
 
What are the possible benefits? 
We hope that this study will prove that measuring these biochemical markers can 
effectively diagnose pregnancy of unknown location. The information we get from this 
study may help us to improve our care of future patients in your situation. This however 
cannot be guaranteed. 
 
Will my taking part in the study be kept confidential? 
All information the collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have 
your name and address removed so that you cannot be recognised from it. 
 
Will I find out the results of the research project? 
Once the study is complete we will contact all participants to let you know what the 
results were.   
 
What should I do if I get pain or bleeding? 
If you develop severe pain or bleeding you should contact us immediately. The ward 
number is 0191 569 9747. Until the final diagnosis is made we advise you not to travel 
outside of the local area and to avoid strenuous exercise. 
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What do I do next? 
If you agree to take part in this research project we will ask you to sign a consent form. 
We will also give you a letter for your doctor. You will be given a copy of this 
information leaflet, with the contact details, and a signed consent form to keep. 
 
If you have any further questions before or during the study you may contact Dr Maya 
Chetty on 0191 565 6256, bleep 57519 
 
 
Thank you for your help. 
 
 
 
Ethical approval no: 05/Q0902/63 
Date approved: 03/02/06 
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Ethical approval number: 05/Q0902/63 
Date approved: 03/02/06  
 
Patient Identification Number for this study: 
 
 
CONSENT FORM 
 
Title of Project:   Prediction of successful expectant management of 
pregnancy of unknown location 
 
Name of Researcher: Dr Janine Elson, Dr Maya Chetty 
         Please initial box 
 
1. I confirm that I have read and understand the information sheet dated ............................  
 (version ............) for the above study and have had the opportunity to ask questions. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time,  
 without giving any reason, without my medical care or legal rights being affected. 
 
 
3. I understand that sections of any of my medical notes may be looked at by responsible 
individuals from the research team and that certain details will be recorded in the research database. I 
give permission for these individuals to have access to my records. 
 
 
4.  I understand that the research notes and database may be looked at by regulatory authorities. I give 
permission for these individuals to have access to these records. 
 
 
 
5. I agree to take part in the above study.       
     
 
 
________________________  ____________________ 
Name of Patient  Signature      
Date  
 
 
_________________________  ____________________ 
Name of Person taking consent                                                                  Signature                  
Date  
(if different from researcher) 
 
 
_________________________  ____________________ 
Researcher  Signature      
Date  
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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Early Pregnancy Assessment Unit 
Department of Gynaecology 
Sunderland Royal Hospital 
Tel: 0191 565 6256 ext 49779 
 
 
Dear Doctor,  
 
Your patient has consented to take part in our study “the value of novel biochemical 
markers in the prediction of successful expectant management of pregnancies of 
unknown location”. One blood sample has been taken after the initial ultrasound scan 
for the analysis of novel biochemical markers. 
 
The study does not involve any additional procedures or hospital visits. 
 
As the value of these markers has not yet been fully evaluated, the care of your patient 
will not be affected. However if they are found to be of value, they may benefit women 
in the future.  
 
If you have any questions regarding the study, please contact Dr Maya Chetty on 0191 
565 6256, bleep 57519. 
 
Yours sincerely, 
 
Dr Maya Chetty                                                Miss Janine Elson 
Research Fellow                                              Consultant Obstetrician and Gynaecologist 
 
Ethical approval no: 05/Q0902/63      
Date approved: 03/02/06 
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Study number: 
 
Hospital number: 
 
Date recruited:    Fertility pt:  Y / N 
 
Maternal age:    Para  + 
 
LMP:      Gestational age: 
 
Bleeding    0  1 
Pain     0  1 
 
Endometrial thickness: 
 
Progesterone  
HCG  
17-OHP  
Inhibin A  
Inhibin pro αC  
IGFBP-1  
 
Outcome:  failed PUL miscarriage ectopic  viable IUP  
Time to diagnosis: 
Time to pregnancy resolution: 
Further treatment required  0  1 
Medical /Surgical 
 
Complications:   0  1 
       Details: 
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